

Targeting EZH2 in cancer

Nature Medicine

22, 128-134

DOI: [10.1038/nm.4036](https://doi.org/10.1038/nm.4036)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Emerging Epigenetic Landscape in Melanoma. , 0, , .		0
2	The microRNA signature of patients with sunitinib failure: regulation of <i>UHRF1</i> pathways by <i>microRNA-101</i> in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 59070-59086.	0.8	66
3	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. <i>Oncotarget</i> , 2016, 7, 59360-59376.	0.8	34
4	Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165005.	1.1	34
5	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	7.7	191
6	LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. <i>Journal of Translational Medicine</i> , 2016, 14, 346.	1.8	86
7	pRB Takes an EZ Path to a Repetitive Task. <i>Molecular Cell</i> , 2016, 64, 1015-1017.	4.5	2
8	Stressing Out About RAD52. <i>Molecular Cell</i> , 2016, 64, 1017-1019.	4.5	16
9	No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. <i>Klinische Padiatrie</i> , 2016, 228, 113-117.	0.2	44
10	EZH2: a pleiotropic protein. <i>Blood</i> , 2016, 128, 888-889.	0.6	6
11	A sniff to chase ill humors away. <i>Blood</i> , 2016, 128, 889-890.	0.6	0
12	A New Chromatin-Cytoskeleton Link in Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 1173-1175.	1.5	3
13	Dysregulation of histone methyltransferases in breast cancer – Opportunities for new targeted therapies?. <i>Molecular Oncology</i> , 2016, 10, 1497-1515.	2.1	56
14	Epigenetic control of the tumor microenvironment. <i>Epigenomics</i> , 2016, 8, 1671-1687.	1.0	66
15	Lack of Transcription Triggers H3K27me3 Accumulation in the Gene Body. <i>Cell Reports</i> , 2016, 16, 696-706.	2.9	65
16	Spatiotemporal expression of <i>Ezh2</i> in the developing mouse cochlear sensory epithelium. <i>Frontiers of Medicine</i> , 2016, 10, 330-335.	1.5	4
17	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. <i>Drug Resistance Updates</i> , 2016, 28, 65-81.	6.5	147
18	Developing EZH2-Targeted Therapy for Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 949-952.	7.7	26

#	ARTICLE	IF	CITATIONS
19	Recently discovered EZH2 and EHMT2 (G9a) inhibitors. <i>Future Medicinal Chemistry</i> , 2016, 8, 1635-1654.	1.1	24
20	Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. <i>International Journal of Hematology</i> , 2016, 104, 281-292.	0.7	44
21	Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice. <i>Journal of Biological Chemistry</i> , 2016, 291, 24594-24606.	1.6	78
22	Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. <i>Diagnostic Pathology</i> , 2016, 11, 137.	0.9	7
23	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
24	Genomic and Epigenomic Alterations in Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1724-1735.	1.9	130
25	Epigenetic balance of gene expression by Polycomb and COMPASS families. <i>Science</i> , 2016, 352, aad9780.	6.0	407
26	Improving understanding of chromatin regulatory proteins and potential implications for drug discovery. <i>Expert Review of Proteomics</i> , 2016, 13, 435-445.	1.3	2
27	Organ-specific gene modulation: Principles and applications in cancer research. <i>Cancer Letters</i> , 2017, 387, 18-24.	3.2	0
28	Order Matters: The Order of Somatic Mutations Influences Cancer Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a027060.	2.9	46
29	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. <i>Epigenetics</i> , 2017, 12, 370-377.	1.3	31
30	MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. <i>Nature Communications</i> , 2017, 8, 14270.	5.8	187
31	A New Role for ERÎ±: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. <i>Molecular Cancer Research</i> , 2017, 15, 152-164.	1.5	25
32	Circ100284, via miR-217 regulation of EZH2, is involved in the arsenite-accelerated cell cycle of human keratinocytes in carcinogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 753-763.	1.8	69
33	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2215-2226.	2.9	86
34	Marked for death: targeting epigenetic changes in cancer. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 241-263.	21.5	244
35	SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1576-1583.	1.0	26
36	Novel therapeutic approaches in chondrosarcoma. <i>Future Oncology</i> , 2017, 13, 637-648.	1.1	96

#	ARTICLE	IF	CITATIONS
37	Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2. ACS Combinatorial Science, 2017, 19, 161-172.	3.8	43
38	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. Blood, 2017, 129, 2420-2428.	0.6	38
39	Epigenetics in cancer: Fundamentals and Beyond. , 2017, 173, 118-134.		174
40	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED). Journal of Medicinal Chemistry, 2017, 60, 2212-2214.	2.9	10
41	EZH2 regulates spinal neuroinflammation in rats with neuropathic pain. Neuroscience, 2017, 349, 106-117.	1.1	61
42	MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post-transcriptional regulation of enhancer of zeste homolog 2. Oncology Reports, 2017, 37, 1682-1690.	1.2	18
43	Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Current Opinion in Genetics and Development, 2017, 42, 56-67.	1.5	142
44	EZH2 inhibitors: a patent review (2014-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 797-813.	2.4	40
45	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports, 2017, 18, 2907-2917.	2.9	61
46	Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Scientific Reports, 2017, 7, 894.	1.6	110
47	Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation. Biochemical Pharmacology, 2017, 137, 61-80.	2.0	32
48	Structure of the PRC2 complex and application to drug discovery. Acta Pharmacologica Sinica, 2017, 38, 963-976.	2.8	35
49	Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. Clinical Cancer Research, 2017, 23, 4817-4830.	3.2	59
50	Epigenetic Control of Osteoblast Differentiation by Enhancer of Zeste Homolog 2 (EZH2). Current Molecular Biology Reports, 2017, 3, 94-106.	0.8	15
51	Transcriptomic analyses of RNA-binding proteins reveal eIF3c promotes cell proliferation in hepatocellular carcinoma. Cancer Science, 2017, 108, 877-885.	1.7	38
52	Polycomb repressive complexes in hematological malignancies. Blood, 2017, 130, 23-29.	0.6	44
53	The LncRNA HOTAIR-expression, regulation and function in cancer. Nucleus (India), 2017, 60, 155-164.	0.9	2
54	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. Cancer Science, 2017, 108, 553-562.	1.7	44

#	ARTICLE	IF	CITATIONS
55	Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms. <i>Leukemia</i> , 2017, 31, 1936-1943.	3.3	23
56	EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. <i>Scientific Reports</i> , 2017, 7, 3568.	1.6	68
57	Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β -Catenin Target Genes. <i>EBioMedicine</i> , 2017, 21, 104-116.	2.7	21
58	Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution. <i>Molecular Cancer Research</i> , 2017, 15, 1127-1137.	1.5	40
59	Notch Represses Transcription by PRC2 Recruitment to the Ternary Complex. <i>Molecular Cancer Research</i> , 2017, 15, 1173-1183.	1.5	12
60	UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor. <i>Oncogene</i> , 2017, 36, 5497-5511.	2.6	45
61	Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists. <i>Tetrahedron Letters</i> , 2017, 58, 2629-2635.	0.7	18
62	Polycomb repressive complex 2 in an autoinhibited state. <i>Journal of Biological Chemistry</i> , 2017, 292, 13323-13332.	1.6	14
63	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 236.	1.1	21
64	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.4	116
65	Prospects for combining targeted and conventional cancer therapy with immunotherapy. <i>Nature Reviews Cancer</i> , 2017, 17, 286-301.	12.8	742
66	Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4376-4387.	3.2	46
67	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. <i>Cell Death and Differentiation</i> , 2017, 24, 889-902.	5.0	53
68	miR-202 Diminishes TGF β 2 Receptors and Attenuates TGF β 2-Induced EMT in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1029-1039.	1.5	38
69	The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion. <i>Tumor Biology</i> , 2017, 39, 101042831769835.	0.8	10
70	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	7.1	35
71	Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. <i>Blood Cancer Journal</i> , 2017, 7, e549-e549.	2.8	81
73	Targeting of Polycomb Repressive Complex 2 to RNA by Short Repeats of Consecutive Guanines. <i>Molecular Cell</i> , 2017, 65, 1056-1067.e5.	4.5	185

#	ARTICLE	IF	CITATIONS
74	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , 2017, 400, 325-335.	3.2	51
75	Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 19, 531-537.	0.8	6
76	Targeting BAP1: a new paradigm for mesothelioma. <i>Lung Cancer</i> , 2017, 109, 145-146.	0.9	6
77	Targeting Chromatin Remodeling in Inflammation and Fibrosis. <i>Advances in Protein Chemistry and Structural Biology</i> , 2017, 107, 1-36.	1.0	26
78	Compositional and functional diversity of canonical PRC1 complexes in mammals. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 233-245.	0.9	34
79	Dynamics of BAFâ€“Polycomb complex opposition on heterochromatin in normal and oncogenic states. <i>Nature Genetics</i> , 2017, 49, 213-222.	9.4	220
80	Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 415-427.	2.9	52
81	MiRâ€“101â€“p Regulates the Viability of Lung Squamous Carcinoma Cells via Targeting <i>EZH2</i> . <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3142-3149.	1.2	18
82	Small-cell lung cancer: what we know, what we need to know and the path forward. <i>Nature Reviews Cancer</i> , 2017, 17, 725-737.	12.8	558
83	EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. <i>Cancer Research</i> , 2017, 77, 6651-6666.	0.4	66
84	DNA Methylationâ€“Targeted Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 270-276.	1.0	27
85	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. <i>Nature Communications</i> , 2017, 8, 877.	5.8	132
86	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. <i>Nature Cell Biology</i> , 2017, 19, 1371-1378.	4.6	257
87	Aberrant chromatin remodeling in gynecological cancer (Review). <i>Oncology Letters</i> , 2017, 14, 5107-5113.	0.8	8
88	CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of <i>Plasmodium falciparum</i> invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9356-E9365.	3.3	43
89	Novel Drugs Targeting the Epigenome. <i>Current Pharmacology Reports</i> , 2017, 3, 268-285.	1.5	2
90	Mutations in myeloproliferative neoplasms â€“ their significance and clinical use. <i>Expert Review of Hematology</i> , 2017, 10, 961-973.	1.0	19
91	DNA and Histone Methylation in Hematopoietic Malignancy. <i>Cancer Drug Discovery and Development</i> , 2017, , 391-401.	0.2	0

#	ARTICLE	IF	CITATIONS
92	Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation. <i>American Journal of Pathology</i> , 2017, 187, 2288-2299.	1.9	62
93	Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer. <i>Epigenomics</i> , 2017, 9, 1329-1335.	1.0	5
94	The role of long non-coding RNA H19 in musculoskeletal system: A new player in an old game. <i>Experimental Cell Research</i> , 2017, 360, 61-65.	1.2	28
95	Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. <i>Cancer Research</i> , 2017, 77, 5602-5613.	0.4	48
96	MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017, 7, 7481.	1.6	38
97	The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. <i>Cell Reports</i> , 2017, 20, 854-867.	2.9	258
98	Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. <i>Human Pathology</i> , 2017, 67, 78-84.	1.1	29
99	EZH2 is involved in silencing of WNT5A during epithelial-to-mesenchymal transition of colon cancer cell line. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2211-2219.	1.2	15
100	Medical treatment of advanced chordomas. <i>European Journal of Cancer</i> , 2017, 83, 220-228.	1.3	45
101	Epigenetic plasticity and the hallmarks of cancer. <i>Science</i> , 2017, 357, .	6.0	920
102	Inhibition of Human Enhancer of Zeste Homolog 2 with Tambjamine Analogs. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 2089-2098.	2.5	5
103	EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis. <i>Oncogene</i> , 2017, 36, 6542-6554.	2.6	36
104	Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. <i>Cancer Science</i> , 2017, 108, 2069-2078.	1.7	95
105	Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens. <i>MBio</i> , 2017, 8, .	1.8	56
106	Potential new strategies for the treatment of renal medullary carcinoma. <i>BJU International</i> , 2017, 120, 744-744.	1.3	0
107	MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1358-1362.	2.5	23
108	NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. <i>Nature Communications</i> , 2017, 8, 1772.	5.8	40
109	EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers. <i>Oncology Letters</i> , 2017, 14, 5735-5742.	0.8	27

#	ARTICLE	IF	CITATIONS
110	SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. <i>Modern Pathology</i> , 2017, 30, 1422-1432.	2.9	135
111	Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). <i>Current Protocols in Pharmacology</i> , 2017, 77, 14.40.1-14.40.19.	4.0	18
112	Epigenetics during EMT in lung cancer: EZH2 as a potential therapeutic target. <i>Cancer Treatment and Research Communications</i> , 2017, 12, 40-48.	0.7	9
113	Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. <i>Carcinogenesis</i> , 2017, 38, 1036-1046.	1.3	163
114	A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. <i>Epigenomics</i> , 2017, 9, 1123-1142.	1.0	125
115	Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 121.	6.9	50
116	Cellular reprogramming technology for dissecting cancer epigenome <i>in vivo</i> . <i>Epigenomics</i> , 2017, 9, 997-1011.	1.0	4
117	Targeting EZH2 in cancer therapy. <i>Current Opinion in Oncology</i> , 2017, 29, 375-381.	1.1	179
118	Recent progress in developing selective inhibitors of protein methyltransferases. <i>Current Opinion in Chemical Biology</i> , 2017, 39, 100-108.	2.8	40
119	Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. <i>Annals of Oncology</i> , 2017, 28, 254-269.	0.6	66
120	Diagnostic utility of <i>BAP1</i> and <i>EZH2</i> expression in malignant mesothelioma. <i>Histopathology</i> , 2017, 70, 722-733.	1.6	63
121	Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 15-25.	5.0	50
122	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017, 241, 173-182.	2.1	36
123	Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. <i>Proteomics</i> , 2017, 17, 1600079.	1.3	64
124	The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 59-71.	5.0	271
125	Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3428-3441.	3.2	109
126	Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2017, 63, 90-97.	0.4	24
127	EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 477-488.	1.5	48

#	ARTICLE	IF	CITATIONS
128	Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. <i>Diseases (Basel)</i> , 2017, 7, 1-17.	1.0	54
129	Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1440.	1.8	7
130	Status of Epstein-Barr Virus Coinfection with <i>Helicobacter pylori</i> in Gastric Cancer. <i>Journal of Oncology</i> , 2017, 2017, 1-17.	0.6	47
131	The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	8
132	Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. <i>PLoS ONE</i> , 2017, 12, e0183155.	1.1	12
133	LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27. <i>Journal of Orthopaedic Surgery and Research</i> , 2017, 12, 103.	0.9	40
134	Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. <i>Cell and Bioscience</i> , 2017, 7, 56.	2.1	40
135	EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 17.	3.6	34
136	Hair keratin KRT81 is expressed in normal and breast cancer cells and contributes to their invasiveness. <i>Oncology Reports</i> , 2017, 37, 2964-2970.	1.2	22
137	Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma. <i>International Journal of Biological Sciences</i> , 2017, 13, 652-659.	2.6	40
138	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 180.	1.8	16
139	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. <i>Genes</i> , 2017, 8, 71.	1.0	78
140	Advances in sarcoma diagnostics and treatment. <i>Oncotarget</i> , 2017, 8, 7068-7093.	0.8	89
141	EZH2 inhibition sensitizes tamoxifen-resistant breast cancer cells through cell cycle regulation. <i>Molecular Medicine Reports</i> , 2017, 17, 2642-2650.	1.1	9
142	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 271-286.	1.9	273
143	EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications. <i>Oncogene</i> , 2018, 37, 2714-2727.	2.6	59
144	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 591-602.	1.9	71
145	Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1070-1078.	1.9	31

#	ARTICLE	IF	CITATIONS
146	Targeting Epigenetic Modifiers for Cancer Treatments. <i>Current Pharmacology Reports</i> , 2018, 4, 193-201.	1.5	0
147	Repressing the repressor: Ezh2 mediates macrophage activation. <i>Journal of Experimental Medicine</i> , 2018, 215, 1269-1271.	4.2	29
148	Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170150.	1.8	13
149	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. <i>Cell Reports</i> , 2018, 23, 823-837.	2.9	42
150	YY1ÂUpregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells. <i>IScience</i> , 2018, 2, 105-122.	1.9	49
151	Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. <i>Molecular Cell</i> , 2018, 70, 422-434.e6.	4.5	100
152	The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2018, 233, 6508-6517.	2.0	19
153	Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer. <i>Scientific Reports</i> , 2018, 8, 5535.	1.6	9
154	The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. <i>Cancer Cell</i> , 2018, 33, 607-619.e15.	7.7	88
155	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 64-79.	2.0	12
156	Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription. <i>Cell Death and Disease</i> , 2018, 9, 238.	2.7	92
157	Ezh2 promotes clock function and hematopoiesis independent of histone methyltransferase activity in zebrafish. <i>Nucleic Acids Research</i> , 2018, 46, 3382-3399.	6.5	24
158	Non-coding RNAs in the reprogramming of glucose metabolism in cancer. <i>Cancer Letters</i> , 2018, 419, 167-174.	3.2	60
159	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. <i>Molecular Cell</i> , 2018, 69, 279-291.e5.	4.5	138
160	Utx loss causes myeloid transformation. <i>Leukemia</i> , 2018, 32, 1458-1465.	3.3	20
161	MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. <i>Oncogene</i> , 2018, 37, 2079-2088.	2.6	50
162	Epigenetic modificationsâ€”insight into oligodendrocyte lineage progression, regeneration, and disease. <i>FEBS Letters</i> , 2018, 592, 1063-1078.	1.3	36
163	Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities. <i>Journal of Pathology</i> , 2018, 244, 638-649.	2.1	30

#	ARTICLE	IF	CITATIONS
164	Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1126-1136.	0.3	25
165	EZH2 overexpression in head and neck cancer is related to lymph node metastasis. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 240-245.	1.4	16
166	SWI/SNF (BAF) Complexes: Guardians of the Epigenome. <i>Annual Review of Cancer Biology</i> , 2018, 2, 413-427.	2.3	31
167	Chromatin remodeling and epigenetic regulation of oligodendrocyte myelination and myelin repair. <i>Molecular and Cellular Neurosciences</i> , 2018, 87, 18-26.	1.0	30
168	Polycomb Repressive Complex 2: Emerging Roles in the Central Nervous System. <i>Neuroscientist</i> , 2018, 24, 208-220.	2.6	22
169	Along the Central Dogma—Controlling Gene Expression with Small Molecules. <i>Annual Review of Biochemistry</i> , 2018, 87, 391-420.	5.0	33
170	Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. <i>Biomarker Research</i> , 2018, 6, 10.	2.8	276
171	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	1.1	20
172	Chromatin reprogramming in breast cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R385-R404.	1.6	17
173	Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. <i>Oncogene</i> , 2018, 37, 3589-3600.	2.6	18
174	Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 831-841.	1.3	22
175	MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. <i>Experimental Cell Research</i> , 2018, 366, 103-113.	1.2	36
176	Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 365-379.	1.5	46
177	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. <i>Surgery Today</i> , 2018, 48, 1-8.	0.7	88
178	Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated downregulation of E-cadherin. <i>Journal of Cellular Physiology</i> , 2018, 233, 1359-1369.	2.0	47
179	Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 38-47.	1.6	16
180	Orchestration of H3K27 methylation: mechanisms and therapeutic implication. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 209-223.	2.4	61
181	PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 145-157.	3.2	26

#	ARTICLE	IF	CITATIONS
182	EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms. <i>Oncogene</i> , 2018, 37, 461-477.	2.6	15
183	Pharmacoeugenetics and Toxicoeugenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 161-185.	4.2	45
184	The persistent organochlorine pesticide endosulfan modulates multiple epigenetic regulators with oncogenic potential in MCF-7 cells. <i>Science of the Total Environment</i> , 2018, 624, 1612-1622.	3.9	24
185	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
186	(â)â€Epigallocatechinâ€gallate and <sc>EZH</sc>2 inhibitor <sc>GSK</sc>343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 58-67.	0.9	14
187	Structure, mechanism, and regulation of polycomb-repressive complex 2. <i>Journal of Biological Chemistry</i> , 2018, 293, 13805-13814.	1.6	60
188	EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. <i>Oncogene</i> , 2018, 37, 208-217.	2.6	79
189	Epigenetic Drivers in Pediatric Medulloblastoma. <i>Cerebellum</i> , 2018, 17, 28-36.	1.4	59
190	HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 589-599.	1.1	48
191	A Role for Monomethylation of Histone H3-K27 in Gene Activity in<i>Drosophila</i>. <i>Genetics</i> , 2018, 208, 1023-1036.	1.2	11
192	Histone Mutations in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 337-351.	2.3	23
193	Notch Signaling Controls Transdifferentiation of Pulmonary Neuroendocrine Cells in Response to Lung Injury. <i>Stem Cells</i> , 2018, 36, 377-391.	1.4	44
194	The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 480-487.	1.8	8
195	Emerging Targeted and Immune-Based Therapies in Sarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 125-135.	0.8	65
196	Frameshift events predict antiâ€PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	190
197	Clinical Epigenetic Therapies Disrupt Sex Chromosome Dosage Compensation in Human Female Cells. , 2018, 2, 2-7.	0.8	4
198	Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, S342-S352.	0.6	23
199	Chromatin Dynamics in Cancer: Epigenetic Parameters and Cellular Fateâ€Histone Variants and Their Chaperones: New Targets?. , 2018, , 372-372.		0

#	ARTICLE	IF	CITATIONS
200	Polycomb repressive complex 2 binds RNA irrespective of stereochemistry. <i>Chemical Communications</i> , 2018, 54, 12061-12064.	2.2	6
201	The Role of Histone Methyltransferases and Long Non-coding RNAs in the Regulation of T Cell Fate Decisions. <i>Frontiers in Immunology</i> , 2018, 9, 2955.	2.2	13
202	A Solid-Phase Approach to Accessing Bisthiether-Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity. <i>Angewandte Chemie</i> , 2018, 130, 17319-17324.	1.6	2
203	A Solid-Phase Approach to Accessing Bisthiether-Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 17073-17078.	7.2	13
204	Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer. <i>Cell Cycle</i> , 2018, 17, 2460-2473.	1.3	6
205	Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. <i>Cell Systems</i> , 2018, 7, 526-536.e6.	2.9	23
206	Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8455-8463.	1.0	22
207	Î²-Element Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2. <i>Frontiers in Pharmacology</i> , 2018, 9, 1413.	1.6	37
208	Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population. <i>Scientific Reports</i> , 2018, 8, 17792.	1.6	16
209	Regulation of Epstein-Barr Virus Life Cycle and Cell Proliferation by Histone H3K27 Methyltransferase EZH2 in Akata Cells. <i>MSphere</i> , 2018, 3, .	1.3	25
210	Dysregulation of miR-6868-5p/FOXM1 circuit contributes to colorectal cancer angiogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 292.	3.5	20
211	EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. <i>Frontiers in Pediatrics</i> , 2018, 6, 328.	0.9	14
212	Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 693-698.	2.1	8
213	The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. <i>Molecular Cancer</i> , 2018, 17, 141.	7.9	259
214	MiR-34 inhibits polycomb repressive complex 2 to modulate chaperone expression and promote healthy brain aging. <i>Nature Communications</i> , 2018, 9, 4188.	5.8	41
215	Epimutation and Cancer: Carcinogenesis Viewed as Error-Prone Inheritance of Epigenetic Information. <i>Journal of Oncology</i> , 2018, 2018, 1-4.	0.6	8
216	Targeting enhancer of zeste homolog 2 protects against acute kidney injury. <i>Cell Death and Disease</i> , 2018, 9, 1067.	2.7	32
217	An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. <i>Scientific Reports</i> , 2018, 8, 13537.	1.6	49

#	ARTICLE	IF	CITATIONS
218	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. <i>Cell</i> , 2018, 175, 186-199.e19.	13.5	166
219	Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity. <i>Epigenomes</i> , 2018, 2, 16.	0.8	18
220	Epigenetic Factors: Key Regulators Targeted in Cancers. , 0, , .		1
221	Epigenetics in Melanoma Development and Drug Resistance. , 2018, , .		1
222	Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity. <i>Advances in Cancer Research</i> , 2018, 138, 1-39.	1.9	1
223	Anti-proliferative benefit of curcumol on human bladder cancer cells via inactivating EZH2 effector. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 798-805.	2.5	28
224	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 603-608.	0.6	24
225	Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation. <i>Nature Communications</i> , 2018, 9, 2080.	5.8	63
226	A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes. <i>Cell Reports</i> , 2018, 23, 1639-1650.	2.9	56
227	Ewing sarcoma. <i>Nature Reviews Disease Primers</i> , 2018, 4, 5.	18.1	500
228	Alterations of Histone Modifications in Cancer. , 2018, , 141-217.		10
229	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018, 34, 69-84.e14.	7.7	123
230	Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes. <i>Cell Reports</i> , 2018, 24, 238-251.	2.9	25
231	Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies. <i>Cancer Science</i> , 2018, 109, 2342-2348.	1.7	31
232	Stem Cells and Cancer. , 2018, , 271-309.		0
233	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 495-504.	0.7	13
234	Sodium Valproate Inhibits Small Cell Lung Cancer Tumor Growth on the Chicken Embryo Chorioallantoic Membrane and Reduces the p53 and EZH2 Expression. <i>Dose-Response</i> , 2018, 16, 155932581877248.	0.7	4
235	ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 176-184.	3.3	69

#	ARTICLE	IF	CITATIONS
236	Effects of four single nucleotide polymorphisms of EZH2 on cancer risk: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 851-865.	1.0	9
237	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. <i>Frontiers in Medicine</i> , 2018, 5, 85.	1.2	182
238	Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 459.	1.1	18
239	2018 ESMO Sarcoma and GIST Symposium: "take-home messages"™ in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	2.0	6
240	p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. <i>Nature Communications</i> , 2018, 9, 2801.	5.8	87
241	Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. <i>Theranostics</i> , 2018, 8, 3007-3021.	4.6	51
242	Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target. <i>Journal of Pathology</i> , 2018, 245, 433-444.	2.1	16
243	ARID1A loss in cancer: Towards a mechanistic understanding. , 2018, 190, 15-23.		97
244	Gain-of-function mutations in DNMT3A in patients with paraganglioma. <i>Genetics in Medicine</i> , 2018, 20, 1644-1651.	1.1	73
245	Atherosclerosis Is an Epigenetic Disease. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 739-742.	3.1	113
246	Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins. <i>Clinical Epigenetics</i> , 2018, 10, 14.	1.8	27
247	Smurfs in Protein Homeostasis, Signaling, and Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 295.	1.3	78
248	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
249	EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 309-318.	2.3	25
250	Modeling association detection in order to discover compounds to inhibit oral cancer. <i>Journal of Biomedical Informatics</i> , 2018, 84, 159-163.	2.5	5
251	Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170080.	1.8	34
252	Ezh2 does not mediate retinal ganglion cell homeostasis or their susceptibility to injury. <i>PLoS ONE</i> , 2018, 13, e0191853.	1.1	10
253	TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4126-4137.	0.4	109

#	ARTICLE	IF	CITATIONS
254	Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. <i>Cell Reports</i> , 2018, 23, 3262-3274.	2.9	207
255	Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators. <i>Drug Discovery Today</i> , 2019, 24, 179-188.	3.2	11
256	O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. <i>Oncogene</i> , 2019, 38, 301-316.	2.6	93
257	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 31-43.	3.6	79
258	Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma. <i>Cell Death and Disease</i> , 2019, 10, 585.	2.7	42
259	Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer. <i>Endocrine Pathology</i> , 2019, 30, 305-311.	5.2	13
261	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. <i>PLoS ONE</i> , 2019, 14, e0220681.	1.1	10
262	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 82.	0.7	68
263	Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma. <i>Anticancer Research</i> , 2019, 39, 4179-4184.	0.5	9
264	4-Nonylphenol-enhanced EZH2 and RNF2 expression, H3K27me3 and H2AK119ub1 marks resulting in silencing of p21 ^{CDKN1A} in vitro. <i>Epigenomics</i> , 2019, 11, 899-916.	1.0	10
265	Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2227-2240.	1.2	27
266	Long noncoding RNA FEZF1-AS1 in human cancers. <i>Clinica Chimica Acta</i> , 2019, 497, 20-26.	0.5	20
267	The Unexpected Noncatalytic Roles of Histone Modifiers in Development and Disease. <i>Trends in Genetics</i> , 2019, 35, 645-657.	2.9	29
268	EZH2 regulates PD-L1 expression via HIF-1 α in non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 201-209.	1.0	51
269	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. <i>Cancers</i> , 2019, 11, 1015.	1.7	21
270	PDGFR- β Signaling Regulates Cardiomyocyte Proliferation and Myocardial Regeneration. <i>Cell Reports</i> , 2019, 28, 966-978.e4.	2.9	44
271	The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1185-1194.	1.9	49
272	MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer. <i>Cancers</i> , 2019, 11, 897.	1.7	52

#	ARTICLE	IF	CITATIONS
273	EZH2 Regulates Intestinal Inflammation and Necroptosis Through the JNK Signaling Pathway in Intestinal Epithelial Cells. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3518-3527.	1.1	28
274	ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. <i>Cancer Cell</i> , 2019, 36, 512-527.e9.	7.7	44
275	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5114.	5.8	64
276	Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression. <i>Digestion</i> , 2021, 102, 227-235.	1.2	19
277	Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients. <i>Scientific Reports</i> , 2019, 9, 15682.	1.6	13
278	Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. <i>Cell Reports</i> , 2019, 29, 1482-1498.e4.	2.9	47
279	PRC2 complex related dysfunction in overgrowth syndromes: A review of <i>EZH2</i> , <i>EED</i> , and <i>SUZ12</i> and their syndromic phenotypes. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2019, 181, 519-531.	0.7	47
280	lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 3.	6.9	175
281	Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 874.	1.1	7
282	Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 850.	1.3	15
283	Updates on Merkel Cell Carcinoma. <i>Dermatologic Clinics</i> , 2019, 37, 489-503.	1.0	23
284	The Dual Roles of the Atypical Protein Kinase Cs in Cancer. <i>Cancer Cell</i> , 2019, 36, 218-235.	7.7	58
285	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 1323-1336.	0.6	37
286	Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing KrÄ¼ppel-like factor 2 expression in human hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7429-7436.	1.0	38
287	LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression. <i>Cell Death and Disease</i> , 2019, 10, 752.	2.7	51
288	A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111715.	2.6	23
289	Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay. <i>Journal of Biochemistry</i> , 2019, 166, 41-50.	0.9	10
290	Maintenance of epigenetic landscape requires CIZ1 and is corrupted in differentiated fibroblasts in long-term culture. <i>Nature Communications</i> , 2019, 10, 460.	5.8	10

#	ARTICLE	IF	CITATIONS
291	Measurement of methylated metabolites using liquid chromatography-mass spectrometry and its biological application. <i>Analytical Methods</i> , 2019, 11, 49-57.	1.3	10
292	Uterine Epithelial Development and Enhancer of Zeste Homolog 2. <i>American Journal of Pathology</i> , 2019, 189, 1176-1177.	1.9	0
293	Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5025-5036.	1.6	37
294	<p>Targeted nanoparticle-mediated LHPP for melanoma treatment</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 3455-3468.	3.3	15
295	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. <i>Genes and Development</i> , 2019, 33, 936-959.	2.7	127
297	Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells. <i>Cell Cycle</i> , 2019, 18, 1745-1758.	1.3	22
298	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. <i>Clinical Cancer Research</i> , 2019, 25, 6392-6405.	3.2	37
299	EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia. <i>Epigenetics</i> , 2019, 14, 1125-1140.	1.3	24
300	Pharmacoeugenetics of EZH2 Inhibitors. , 2019, , 447-462.		0
301	Epigenetics of Aging and Cancer: A Comprehensive Look. , 2019, , 885-901.		0
302	Atypical Teratoid Rhabdoid Tumors. , 2019, , 615-629.		0
303	EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically. <i>DNA and Cell Biology</i> , 2019, 38, 651-659.	0.9	9
304	ATRX tames repetitive DNA within heterochromatin to promote normal brain development and regulate oncogenesis. , 2019, , 235-257.		0
305	Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 565-578.	1.5	22
306	C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1457-1465.	2.8	7
307	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. <i>Nature Communications</i> , 2019, 10, 2571.	5.8	153
308	PRC2 is high maintenance. <i>Genes and Development</i> , 2019, 33, 903-935.	2.7	197
309	EZH2 Regulates Protein Stability via Recruiting USP7 to Mediate Neuronal Gene Expression in Cancer Cells. <i>Frontiers in Genetics</i> , 2019, 10, 422.	1.1	31

#	ARTICLE	IF	CITATIONS
310	Pharmacological Modulation of Transcriptional Coregulators in Cancer. Trends in Pharmacological Sciences, 2019, 40, 388-402.	4.0	9
311	Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival. Pathobiology, 2019, 86, 152-161.	1.9	25
312	Epigenetics in cancer therapy and nanomedicine. Clinical Epigenetics, 2019, 11, 81.	1.8	147
313	Perturbing Enhancer Activity in Cancer Therapy. Cancers, 2019, 11, 634.	1.7	14
314	Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells. Frontiers in Oncology, 2019, 9, 385.	1.3	12
315	Exposure time versus cytotoxicity for anticancer agents. Cancer Chemotherapy and Pharmacology, 2019, 84, 359-371.	1.1	13
316	Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9622-9627.	3.3	79
317	Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. Expert Review of Anticancer Therapy, 2019, 19, 375-391.	1.1	30
318	The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion. Archives of Pharmacal Research, 2019, 42, 519-530.	2.7	14
319	Assessment of epigenetic mechanisms and DNA double-strand break repair using laser micro-irradiation technique developed for hematological cells. EBioMedicine, 2019, 43, 138-149.	2.7	5
320	Prognostic role of ARID1A negative expression in gastric cancer. Scientific Reports, 2019, 9, 6769.	1.6	34
321	Enantiomeric pairs of ternary copper(ii) complexes and their aldol-type condensation products: synthesis, characterization, and anticancer and epigenetic properties. Dalton Transactions, 2019, 48, 4987-4999.	1.6	9
322	Dual roles of EZH2 in acute myeloid leukemia. Journal of Experimental Medicine, 2019, 216, 725-727.	4.2	14
323	LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomedicine and Pharmacotherapy, 2019, 112, 108719.	2.5	43
324	Integrated Bioinformatics Analysis the Function of RNA Binding Proteins (RBPs) and Their Prognostic Value in Breast Cancer. Frontiers in Pharmacology, 2019, 10, 140.	1.6	59
325	Inhibition of Ezh2 In Vitro and the Decline of <i>Ezh2</i> in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3. Stem Cells and Development, 2019, 28, 649-658.	1.1	4
326	Making Sense of the Epigenome Using Data Integration Approaches. Frontiers in Pharmacology, 2019, 10, 126.	1.6	58
327	Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Lung Cancer, 2019, 130, 187-193.	0.9	35

#	ARTICLE	IF	CITATIONS
328	Emerging therapeutic targets for patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2019, 76, 1-9.	3.4	26
329	Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes. <i>Molecular Carcinogenesis</i> , 2019, 58, 1194-1207.	1.3	45
330	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003566.	0.5	6
331	SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Discussion of the Clinical Implications. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2019, 128, 676-680.	0.6	15
332	Phytochemical Modulation of MiRNAs in Colorectal Cancer. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 48.	0.7	9
333	TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma. <i>Oncogenesis</i> , 2019, 8, 27.	2.1	8
334	Decreased expression of NEDD4L contributes to NSCLC progression and metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 398-404.	1.0	26
335	EZH1/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 878-889.	0.6	106
336	Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. <i>Nature Communications</i> , 2019, 10, 1436.	5.8	33
337	Emerging role of PI3K/AKT in tumor-related epigenetic regulation. <i>Seminars in Cancer Biology</i> , 2019, 59, 112-124.	4.3	113
338	EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 2009-2020.	0.4	112
340	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , 2019, 20, 581-590.	5.1	124
341	Regulation of Polycomb Repression by O-GlcNAcylation: Linking Nutrition to Epigenetic Reprogramming in Embryonic Development and Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 117.	1.5	15
342	Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival. <i>Scientific Reports</i> , 2019, 9, 1974.	1.6	19
343	The synergistic effect of DZNep, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. <i>International Journal of Oncology</i> , 2020, 56, 283-300.	1.4	9
344	Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response. <i>Molecular Cancer Research</i> , 2020, 18, 253-263.	1.5	19
345	Explore the correlation between ARID1A and ANXA1 expressions in gastric cancer. <i>Annals of Cancer Research and Therapy</i> , 2019, 27, 46-51.	0.1	1
346	Lysine Methyltransferases and Their Inhibitors. <i>Topics in Medicinal Chemistry</i> , 2019, , 123-157.	0.4	0

#	ARTICLE	IF	CITATIONS
347	Epigenetic modifications of histones in cancer. <i>Genome Biology</i> , 2019, 20, 245.	3.8	322
349	Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 350.	1.8	44
350	Molecular regulation of Snai2 in development and disease. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	71
351	Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-13.	3.2	62
352	<p>Long Non-Coding RNA HOXA-AS2 Enhances The Malignant Biological Behaviors In Glioma By Epigenetically Regulating RND3 Expression</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9407-9419.	1.0	18
353	Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor. <i>Molecules</i> , 2019, 24, 4492.	1.7	36
355	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. <i>Oncogene</i> , 2019, 38, 671-686.	2.6	39
356	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
357	Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. <i>Cancer Cell</i> , 2019, 35, 81-94.e7.	7.7	64
358	ALK and EGFR expression by immunohistochemistry are associated with Merkel cell polyomavirus status in Merkel cell carcinoma. <i>Histopathology</i> , 2019, 74, 829-835.	1.6	7
359	Oral Cancer Detection. , 2019, , .		13
360	miRâ€24â€3p attenuates neuropathic pain induced by chronic sciatic nerve injury in rats via targeting EZH2. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5747-5755.	1.2	42
361	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. , 2019, 196, 15-43.		110
362	Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 139-149.	1.1	16
363	Dual inhibition of enhancer of zeste homolog 1/2 overactivates <sc>WNT</sc> signaling to deplete cancer stem cells in multiple myeloma. <i>Cancer Science</i> , 2019, 110, 194-208.	1.7	18
364	CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. <i>Haematologica</i> , 2019, 104, 226-235.	1.7	38
365	CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer. <i>Scientific Reports</i> , 2019, 9, 197.	1.6	30
366	Genetics and Molecular Mechanisms in Oral Cancer Progression. , 2019, , 29-80.		1

#	ARTICLE	IF	CITATIONS
367	Towards understanding of PRC2 binding to RNA. <i>RNA Biology</i> , 2019, 16, 176-184.	1.5	40
368	Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. <i>BMC Cancer</i> , 2019, 19, 27.	1.1	26
369	Polycomb complexes in normal and malignant hematopoiesis. <i>Journal of Cell Biology</i> , 2019, 218, 55-69.	2.3	52
370	A framework for identifying dysregulated chromatin regulators as master regulators in human cancer. <i>Bioinformatics</i> , 2019, 35, 1805-1812.	1.8	2
372	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	3.2	48
373	Targeting Cancer at the Intersection of Signaling and Epigenetics. <i>Annual Review of Cancer Biology</i> , 2019, 3, 365-384.	2.3	4
374	Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2019, 127, 69-75.	0.9	19
376	Effect of the key histone modifications on the expression of genes related to breast cancer. <i>Genomics</i> , 2020, 112, 853-858.	1.3	14
377	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
378	Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 290-300.	3.2	142
379	The great escape: tumour cell plasticity in resistance to targeted therapy. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 39-56.	21.5	439
380	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2020, 39, 6265-6285.	2.6	52
381	Chromatin modification and epigenetic control in functional nerve regeneration. <i>Seminars in Cell and Developmental Biology</i> , 2020, 97, 74-83.	2.3	6
382	Translational genomics of ovarian clear cell carcinoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 121-131.	4.3	25
383	Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities. <i>Seminars in Cancer Biology</i> , 2020, 61, 30-41.	4.3	17
384	Mice lacking uterine enhancer of zeste homolog 2 have transcriptomic changes associated with uterine epithelial proliferation. <i>Physiological Genomics</i> , 2020, 52, 81-95.	1.0	9
385	EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer. <i>Biotechnology and Applied Biochemistry</i> , 2020, 67, 1011-1019.	1.4	43
386	Interweaving Tumor Heterogeneity into the Cancer Epigenetic/Metabolic Axis. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 946-965.	2.5	2

#	ARTICLE	IF	CITATIONS
387	The â€œARTâ€•of Epigenetics in Melanoma: From histone â€œAlterations, to Resistance and Therapiesâ€•: Theranostics, 2020, 10, 1777-1797.	4.6	44
388	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars in Cancer Biology, 2020, 65, 114-122.	4.3	45
389	UNC5Bâ€•AS1 promoted ovarian cancer progression by regulating the H3K27me on NDRG2 via EZH2. Cell Biology International, 2020, 44, 1028-1036.	1.4	21
390	Binding Modes of Smallâ€•Molecule Inhibitors to the EED Pocket of PRC2. ChemPhysChem, 2020, 21, 263-271.	1.0	11
391	Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology, 2020, 16, 214-222.	3.9	148
392	Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines. Journal of Proteomics, 2020, 213, 103614.	1.2	1
393	A lncRNA coordinates with Ezh2 to inhibit HIF-1Î± transcription and suppress cancer cell adaption to hypoxia. Oncogene, 2020, 39, 1860-1874.	2.6	35
394	LncRNA SNHG15: A new budding star in human cancers. Cell Proliferation, 2020, 53, e12716.	2.4	38
395	EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2020, 24, 1640-1649.	1.6	8
396	EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell Chemical Biology, 2020, 27, 41-46.e17.	2.5	131
397	MicroRNA-33b Suppresses Epithelialâ€•Mesenchymal Transition Repressing the MYCâ€•EZH2 Pathway in HER2+ Breast Carcinoma. Frontiers in Oncology, 2020, 10, 1661.	1.3	9
398	A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy. Molecular Therapy - Oncolytics, 2020, 19, 79-92.	2.0	29
399	Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Letters, 2020, 495, 41-52.	3.2	17
400	linc00174-EZH2-ZNF24/Runx1-VEGFA Regulatory Mechanism Modulates Post-burn Wound Healing. Molecular Therapy - Nucleic Acids, 2020, 21, 824-836.	2.3	25
401	2-Oxoglutarate-dependent dioxygenases in cancer. Nature Reviews Cancer, 2020, 20, 710-726.	12.8	119
402	High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Annals of Diagnostic Pathology, 2020, 49, 151622.	0.6	11
403	A modern era of personalized medicine in the diagnosis, prognosis, and treatment of prostate cancer. Computers in Biology and Medicine, 2020, 126, 104020.	3.9	9
404	EZH2 in Myeloid Malignancies. Cells, 2020, 9, 1639.	1.8	37

#	ARTICLE	IF	CITATIONS
405	Epigenetic Regulation of Skeletal Tissue Integrity and Osteoporosis Development. International Journal of Molecular Sciences, 2020, 21, 4923.	1.8	11
406	Present and future perspectives for targeting histone modifications in therapy. , 2020, , 415-457.		1
407	Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis. BioMed Research International, 2020, 2020, 1-13.	0.9	8
408	EZH2 as a Potential Target for NAFLD Therapy. International Journal of Molecular Sciences, 2020, 21, 8617.	1.8	17
409	Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer. BMC Cancer, 2020, 20, 1159.	1.1	17
410	Morphine leads to global genome changes in H3K27me3 levels via a Polycomb Repressive Complex 2 (PRC2) self-regulatory mechanism in mESCs. Clinical Epigenetics, 2020, 12, 170.	1.8	4
411	Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells. Cell Death and Disease, 2020, 11, 1024.	2.7	10
412	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	4.5	54
413	Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage. Frontiers in Genetics, 2020, 11, 857.	1.1	14
414	Epigenetic Therapies for Cancer. New England Journal of Medicine, 2020, 383, 650-663.	13.9	289
415	EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Theranostics, 2020, 10, 8494-8512.	4.6	65
416	Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. Frontiers in Cell and Developmental Biology, 2020, 8, 546.	1.8	33
417	<i>EZH2</i> -activating mutation: no reliable indicator for efficacy of methyltransferase inhibitors. Leukemia and Lymphoma, 2020, 61, 2885-2893.	0.6	1
418	The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Medicinal Chemistry, 2020, 12, 1415-1430.	1.1	16
419	Cancer-Related Increases and Decreases in Calcium Signaling at the Endoplasmic Reticulum-Mitochondria Interface (MAMs). Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 153-193.	0.9	13
420	Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine and Pharmacotherapy, 2020, 130, 110626.	2.5	25
421	Targeting DNA Repair Pathways in Hematological Malignancies. International Journal of Molecular Sciences, 2020, 21, 7365.	1.8	10
422	Phenotypes from cell-free DNA. Open Biology, 2020, 10, 200119.	1.5	9

#	ARTICLE	IF	CITATIONS
423	CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 561804.	1.8	7
424	Macrophages-stimulated PRMT1-mediated EZH2 methylation promotes breast cancer metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 679-684.	1.0	19
425	Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 229.	3.5	23
426	Overgrowth Syndromesâ€”Evaluation, Diagnosis, and Management. <i>Frontiers in Pediatrics</i> , 2020, 8, 574857.	0.9	38
427	Role of Polycomb Complexes in Normal and Malignant Plasma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8047.	1.8	9
428	Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. <i>Biochemical Pharmacology</i> , 2020, 182, 114224.	2.0	49
429	A novel antiviral lncRNA, EDAL, shields a T309 O-GlcNAcylation site to promote EZH2 lysosomal degradation. <i>Genome Biology</i> , 2020, 21, 228.	3.8	38
430	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6176.	1.8	19
431	Study and analysis of antitumor resistance mechanism of PD1/PDâ€1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
432	Integrative profiling analysis identifies the oncogenic long noncoding RNA DUXAP8 in oral cancer. <i>Anti-Cancer Drugs</i> , 2020, 31, 792-798.	0.7	14
433	EZH2-Targeted Therapies in Cancer: Hype or a Reality. <i>Cancer Research</i> , 2020, 80, 5449-5458.	0.4	139
434	Gender Differential Transcriptome in Gastric and Thyroid Cancers. <i>Frontiers in Genetics</i> , 2020, 11, 808.	1.1	11
435	Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2023-2033.	1.9	15
436	A fourâ€gene signature associated with clinical features can better predict prognosis in prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 8202-8215.	1.3	8
437	Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer. <i>Theranostics</i> , 2020, 10, 10016-10030.	4.6	21
438	EZH2 inhibition: aâ€promisingâ€strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020, 12, 1457-1476.	1.0	37
439	Radiosynthesis of [11C]E11 for imaging EZH2 using positron emission tomography. <i>Medicinal Chemistry Research</i> , 2020, 29, 2106-2111.	1.1	0
440	Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. <i>Cell Death and Differentiation</i> , 2020, 27, 3226-3242.	5.0	87

#	ARTICLE	IF	CITATIONS
441	SETting Up for Epigenetic Regulation of Advanced Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 309-311.	7.7	3
442	Same Script, Different Cast: Different Cell Origins Shape Molecular Features and Therapeutic Response in Glioblastoma. <i>Cancer Cell</i> , 2020, 38, 311-313.	7.7	4
443	COCOA: coordinate covariation analysis of epigenetic heterogeneity. <i>Genome Biology</i> , 2020, 21, 240.	3.8	10
444	Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 2541.	1.7	6
445	E2F7 ^{hi} EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression. <i>British Journal of Cancer</i> , 2020, 123, 1445-1455.	2.9	47
446	The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9455.	1.8	9
447	Metabolic Regulation of Epigenetic Modifications and Cell Differentiation in Cancer. <i>Cancers</i> , 2020, 12, 3788.	1.7	21
448	Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. <i>Cells</i> , 2020, 9, 2721.	1.8	13
449	Perspective in Alternative Splicing Coupled to Nonsense-Mediated mRNA Decay. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9424.	1.8	39
450	EZH2-Inhibited MicroRNA-454-3p Promotes M2 Macrophage Polarization in Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 574940.	1.8	20
452	Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 602542.	1.1	7
453	Post-translational modifications of EZH2 in cancer. <i>Cell and Bioscience</i> , 2020, 10, 143.	2.1	47
454	BTEB2-Activated lncRNA TSPEAR-AS2 Drives GC Progression through Suppressing GJA1 Expression and Upregulating CLDN4 Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 1129-1141.	2.3	9
455	Epigenetic Role of Histone Lysine Methyltransferase and Demethylase on the Expression of Transcription Factors Associated with the Epithelial-to-Mesenchymal Transition of Lung Adenocarcinoma Metastasis to the Brain. <i>Cancers</i> , 2020, 12, 3632.	1.7	11
456	Epigenetic Mechanisms in Canine Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 591843.	1.3	9
457	The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta. <i>Epigenomes</i> , 2020, 4, 20.	0.8	6
458	<p>Upregulated Long Non-Coding RNA LL22NC03-N64E9.1 Promotes the Proliferation and Migration of Human Breast Cancer Cells by Silencing Kruppel-Like Factor 2 Expression</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10763-10770.	0.9	3
459	Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?. <i>Cancers</i> , 2020, 12, 3194.	1.7	6

#	ARTICLE	IF	CITATIONS
460	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29
461	Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data. <i>Gynecologic Oncology</i> , 2020, 158, 92-98.	0.6	11
462	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by <i>EZH1</i> and <i>EZH2</i> . <i>PLoS Genetics</i> , 2020, 16, e1008796.	1.5	42
463	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. <i>Blood</i> , 2020, 135, 2337-2353.	0.6	49
464	Circular RNA: A novel potential biomarker for skin diseases. <i>Pharmacological Research</i> , 2020, 158, 104841.	3.1	37
465	<i>EZH2</i> Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2442-2454.e5.	0.3	46
466	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of <i>AHCY</i> in a B-cell lymphoma model. <i>BMC Cancer</i> , 2020, 20, 427.	1.1	3
467	Using Chemical Epigenetics to Target Cancer. <i>Molecular Cell</i> , 2020, 78, 1086-1095.	4.5	40
468	Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4134.	1.8	9
469	The polycomb proteins <i>EZH1</i> and <i>EZH2</i> co-regulate chromatin accessibility and nephron progenitor cell lifespan in mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 11542-11558.	1.6	18
470	When Oxidative Stress Meets Epigenetics: Implications in Cancer Development. <i>Antioxidants</i> , 2020, 9, 468.	2.2	42
471	Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 64.	6.9	113
472	Emerging themes in cohesin cancer biology. <i>Nature Reviews Cancer</i> , 2020, 20, 504-515.	12.8	71
473	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 220-229.	1.3	4
474	The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor. <i>Genes</i> , 2020, 11, 287.	1.0	17
475	<i>EZH2</i> inhibition promotes <i>ANGPTL4/CREB1</i> to suppress the progression of ulcerative colitis. <i>Life Sciences</i> , 2020, 250, 117553.	2.0	10
476	Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy. <i>Epigenomes</i> , 2020, 4, 3.	0.8	9
477	<i>BRAF</i> inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. <i>Neoplasia</i> , 2020, 22, 376-389.	2.3	14

#	ARTICLE	IF	CITATIONS
478	Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1797-1808.	1.9	9
479	A partially disordered region connects gene repression and activation functions of EZH2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16992-17002.	3.3	36
480	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 470-479.	0.6	103
481	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	0.5	119
482	Replisome genes regulation by antitumor miR-101a-5p in clear cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1392-1406.	1.7	22
483	Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. <i>Drug Resistance Updates</i> , 2020, 50, 100683.	6.5	90
484	EZH2 deficiency attenuates Treg differentiation in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 108, 102404.	3.0	42
485	LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2. <i>Life Sciences</i> , 2020, 243, 117295.	2.0	18
486	E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2157-2168.	1.6	23
487	Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. <i>EBioMedicine</i> , 2020, 52, 102632.	2.7	47
488	Transcriptional Regulation at DSBs: Mechanisms and Consequences. <i>Trends in Genetics</i> , 2020, 36, 981-997.	2.9	42
489	A Feedback Circuitry between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 675-688.	0.4	25
490	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. <i>Molecular Immunology</i> , 2020, 119, 35-45.	1.0	28
491	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2020, 30, 755-770.e6.	2.9	65
492	Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. <i>PLoS ONE</i> , 2020, 15, e0227986.	1.1	33
493	Wnt/Catenin Preserves the Stem State of Murine Bone Marrow Stromal Cells Through Activation of EZH2. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1149-1162.	3.1	42
494	LncRNA NR-104098 Inhibits AML Proliferation and Induces Differentiation Through Repressing EZH2 Transcription by Interacting With E2F1. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 142.	1.8	21
495	Genomic-guided precision therapy for soft tissue sarcoma. <i>ESMO Open</i> , 2020, 5, e000626.	2.0	7

#	ARTICLE	IF	CITATIONS
496	Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2. <i>Journal of Biological Chemistry</i> , 2020, 295, 7877-7893.	1.6	51
497	EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma. <i>Anticancer Research</i> , 2020, 40, 2133-2139.	0.5	4
498	Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p/EZH2 axis. <i>Theranostics</i> , 2020, 10, 4705-4719.	4.6	82
499	Epigenetic Therapy for Epithelioid Sarcoma. <i>Cell</i> , 2020, 181, 211.	13.5	47
500	The SWI/SNF complex in cancer – biology, biomarkers and therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 435-448.	12.5	297
501	Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 57-72.	1.8	10
502	Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 382-393.	0.4	30
503	Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. <i>Cancer Discovery</i> , 2020, 10, 980-997.	7.7	44
504	Therapeutic Effects of Curcumol in Several Diseases; An Overview. <i>Nutrition and Cancer</i> , 2021, 73, 181-195.	0.9	39
505	Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 60-71.	2.7	17
506	Inhibition of EZH2 and activation of ERR β synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway. <i>Gastric Cancer</i> , 2021, 24, 72-84.	2.7	16
507	Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells. <i>Epigenetics</i> , 2021, 16, 144-161.	1.3	17
508	Downregulation of miR-326 and its host gene <i>p18</i> arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	2.1	8
509	The therapeutic potential of PROTACs. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 1-24.	2.4	29
510	Cause and effect in epigenetics – where lies the truth, and how can experiments reveal it?. <i>BioEssays</i> , 2021, 43, e2000262.	1.2	3
511	Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes. <i>Breast Cancer</i> , 2021, 28, 496-505.	1.3	7
512	LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. <i>Seminars in Cancer Biology</i> , 2021, 73, 134-157.	4.3	30
513	Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice. <i>Endocrine Pathology</i> , 2021, 32, 17-34.	5.2	34

#	ARTICLE	IF	CITATIONS
514	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. <i>Immunity</i> , 2021, 54, 116-131.e10.	6.6	72
515	Nuclear functions of microRNAs relevant to the cardiovascular system. <i>Translational Research</i> , 2021, 230, 151-163.	2.2	5
516	Regulating Tumor Hypoxia-Modulating OsS Nanoparticles. <i>Small</i> , 2021, 17, e2005086.	5.2	16
517	Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 103-116.	0.9	31
518	Typical and Atypical Carcinoid Tumors of the Mediastinum: A Biomarker Analysis of 27 Cases With Clinical Correlation. <i>International Journal of Surgical Pathology</i> , 2021, 29, 358-367.	0.4	5
519	LINC01436 Inhibited miR-585-3p Expression and Upregulated MAPK1 Expression to Promote Gastric Cancer Progression. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1885-1894.	1.1	14
520	Dynamic Shared Pharmacophore Approach as Tool to Design New Allosteric PRC2 Inhibitors, Targeting EED Binding Pocket. <i>Molecular Informatics</i> , 2021, 40, 2000148.	1.4	1
521	Long Non-coding RNAs in Gammaherpesvirus Infections: Their Roles in Tumorigenic Mechanisms. <i>Frontiers in Microbiology</i> , 2020, 11, 604536.	1.5	4
522	Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor. <i>International Journal of Biological Sciences</i> , 2021, 17, 3760-3775.	2.6	22
523	Preventing phenotypic plasticity in cancer to mitigate therapy resistance. , 2021, , 119-160.		0
524	Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2. <i>Theranostics</i> , 2021, 11, 6891-6904.	4.6	25
527	The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na+ and Mg2+ Cations. <i>Dose-Response</i> , 2021, 19, 155932582199016.	0.7	3
528	LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1. <i>Journal of Translational Medicine</i> , 2021, 19, 45.	1.8	24
529	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 265-286.	21.5	116
530	Hallmarks of cancer—the new testament. <i>Open Biology</i> , 2021, 11, 200358.	1.5	104
531	Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab096.	0.4	13
532	Molecular Mechanisms of Hepatoblastoma. <i>Seminars in Liver Disease</i> , 2021, 41, 028-041.	1.8	19
533	Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 953-963.	1.1	11

#	ARTICLE	IF	CITATIONS
534	Loss and revival of androgen receptor signaling in advanced prostate cancer. <i>Oncogene</i> , 2021, 40, 1205-1216.	2.6	69
535	LINC10536 Attenuates Lung Adenocarcinoma Proliferation and Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
537	Progress Update in Pediatric Renal Tumors. <i>Current Oncology Reports</i> , 2021, 23, 33.	1.8	14
538	Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). <i>Phytotherapy Research</i> , 2021, 35, 3649-3664.	2.8	12
539	Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer. <i>Aging</i> , 2021, 13, 7397-7415.	1.4	7
540	Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method. <i>Journal of Computer-Aided Molecular Design</i> , 2021, 35, 601-611.	1.3	5
541	Molecular profiling of epigenetic landscape of cancer cells during extracellular matrix detachment. <i>Scientific Reports</i> , 2021, 11, 2784.	1.6	3
542	Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases. <i>Frontiers in Physiology</i> , 2021, 12, 640700.	1.3	28
543	Clinical advances in targeting epigenetics for cancer therapy. <i>FEBS Journal</i> , 2022, 289, 1214-1239.	2.2	42
544	Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2829-2848.	2.9	72
545	Epigenetic Alterations in Triple-Negative Breast Cancer—The Critical Role of Extracellular Matrix. <i>Cancers</i> , 2021, 13, 713.	1.7	35
546	The noncanonical role of EZH2 in cancer. <i>Cancer Science</i> , 2021, 112, 1376-1382.	1.7	40
548	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021, 7, .	4.7	28
549	Progress in research of EZH2 in digestive system tumors. <i>World Chinese Journal of Digestology</i> , 2021, 29, 242-247.	0.0	0
550	EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth. <i>PLoS ONE</i> , 2021, 16, e0246244.	1.1	15
551	DZNep attenuates allergic airway inflammation in an ovalbumin-induced murine model. <i>Molecular Immunology</i> , 2021, 131, 60-67.	1.0	3
552	Breast Cancer and the Other Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3280.	1.8	17
553	Implication of EZH2 in the Pro-Proliferative and Apoptosis-Resistant Phenotype of Pulmonary Artery Smooth Muscle Cells in PAH: A Transcriptomic and Proteomic Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2957.	1.8	9

#	ARTICLE	IF	CITATIONS
554	Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects. Russian Journal of Genetics, 2021, 57, 258-272.	0.2	5
555	NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology, 2021, 4, 312.	2.0	16
556	Roles Played by YY1 in Embryonic, Adult and Cancer Stem Cells. Stem Cell Reviews and Reports, 2021, 17, 1590-1606.	1.7	16
557	SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma. Pathology Research and Practice, 2021, 219, 153341.	1.0	8
558	Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C. Epigenomes, 2021, 5, 7.	0.8	2
559	Genetic Alteration Profiles and Clinicopathological Associations in Atypical Parathyroid Adenoma. International Journal of Genomics, 2021, 2021, 1-9.	0.8	7
560	EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice. Frontiers in Immunology, 2021, 12, 653989.	2.2	17
561	Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. Cancers, 2021, 13, 1162.	1.7	16
562	EZH2 and SMYD3 expression in papillary thyroid cancer. Oncology Letters, 2021, 21, 342.	0.8	8
563	WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research, 2021, Volume 13, 2483-2498.	0.9	6
564	The roles of Polycomb repressive complexes in mammalian development and cancer. Nature Reviews Molecular Cell Biology, 2021, 22, 326-345.	16.1	210
566	Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors. Clinical Epigenetics, 2021, 13, 62.	1.8	42
567	Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science Advances, 2021, 7, .	4.7	37
568	Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase. Endocrinology, 2021, 162, .	1.4	7
569	SMARCB1-deficient sinonasal carcinoma: a case report and literature review. Journal of Surgical Case Reports, 2021, 2021, rjab161.	0.2	4
570	Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science, 2021, 28, 27.	2.6	103
571	Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Cancers, 2021, 13, 1746.	1.7	7
572	The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Developmental Cell, 2021, 56, 1100-1117.e9.	3.1	63

#	ARTICLE	IF	CITATIONS
573	Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study. <i>Pathology and Oncology Research</i> , 2021, 27, 600073.	0.9	4
574	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
575	LncRNA LINC-PINT Inhibits Malignant Behaviors of Laryngeal Squamous Cell Carcinoma Cells via Inhibiting ZEB1. <i>Pathology and Oncology Research</i> , 2021, 27, 584466.	0.9	7
576	Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells <i>in vitro</i> . <i>Cancer Biology and Therapy</i> , 2021, 22, 333-344.	1.5	6
577	Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. <i>Future Oncology</i> , 2021, 17, 1253-1263.	1.1	17
578	Epigenetic and metabolic interplay in cutaneous squamous cell carcinoma. <i>Experimental Dermatology</i> , 2021, 30, 1115-1125.	1.4	6
579	Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 27, 482-488.	0.8	7
580	Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development. <i>Cancers</i> , 2021, 13, 2402.	1.7	21
581	Cell-specific epigenetic changes in atherosclerosis. <i>Clinical Science</i> , 2021, 135, 1165-1187.	1.8	14
582	Leveraging epigenetics to enhance the efficacy of immunotherapy. <i>Clinical Epigenetics</i> , 2021, 13, 115.	1.8	24
583	LncRNA TUG1 inhibits the cancer stem cell-like properties of temozolomide-resistant glioma cells by interacting with EZH2. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	15
584	CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. <i>Cancer Science</i> , 2021, 112, 2314-2324.	1.7	12
585	Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer. <i>American Journal of Pathology</i> , 2021, 191, 774-783.	1.9	20
586	LINC02678 as a Novel Prognostic Marker Promotes Aggressive Non-small-cell Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 686975.	1.8	6
587	Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 482.	2.7	13
588	Epigenetic-Based Therapy—A Prospective Chance for Medulloblastoma Patients' Recovery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4925.	1.8	2
589	Advancing targeted protein degradation for cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 638-654.	12.8	251
590	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6305.	1.8	20

#	ARTICLE	IF	CITATIONS
591	Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 841.	0.8	6
592	The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond. <i>Cancers</i> , 2021, 13, 3115.	1.7	6
593	Indispensable epigenetic control of thymic epithelial cell development and function by polycomb repressive complex 2. <i>Nature Communications</i> , 2021, 12, 3933.	5.8	7
594	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. <i>Cancers</i> , 2021, 13, 3155.	1.7	14
595	Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8194-8207.	2.9	25
597	Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. <i>PLoS Computational Biology</i> , 2021, 17, e1008408.	1.5	8
599	The Roles of DNA Demethylases in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 628.	1.7	4
600	Epigenetic Deregulation of Apoptosis in Cancers. <i>Cancers</i> , 2021, 13, 3210.	1.7	29
601	Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation. <i>Gastroenterology</i> , 2021, 160, 2267-2282.	0.6	15
602	Targeting epigenetic mechanisms to overcome venetoclax resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119047.	1.9	7
603	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. <i>Viruses</i> , 2021, 13, 1351.	1.5	1
604	EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	37
605	Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10167-10184.	2.9	50
606	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , 2021, 18, 581-596.	1.9	65
607	PHF19 inhibition as a therapeutic target in multiple myeloma. <i>Current Research in Translational Medicine</i> , 2021, 69, 103290.	1.2	5
608	Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2021-107747.	1.5	2
609	Epigenetic Regulation of Breast Cancer Stem Cells Contributing to Carcinogenesis and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8113.	1.8	13
610	Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1868-1879.	1.9	8

#	ARTICLE	IF	CITATIONS
612	Gene Transcription as a Therapeutic Target in Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7340.	1.8	1
613	Histoneâ€œdeacetylase 8 drives the immune response and the growth of glioma. <i>Glia</i> , 2021, 69, 2682-2698.	2.5	14
614	Methyltransferases in the Pathogenesis of Keratinocyte Cancers. <i>Cancers</i> , 2021, 13, 3402.	1.7	4
615	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. <i>Biochemistry</i> , 2021, 60, 2275-2284.	1.2	2
616	Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options. <i>Head and Neck Pathology</i> , 2022, 16, 596-601.	1.3	11
617	CENPL, ISG20L2, LSM4, MRPL3 are four novel hub genes and may serve as diagnostic and prognostic markers in breast cancer. <i>Scientific Reports</i> , 2021, 11, 15610.	1.6	23
618	NBPF4 mitigates progression in colorectal cancer through the regulation of EZH2â€œassociated ETFA. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9038-9050.	1.6	3
619	CCL5/CCR5 axis in human diseases and related treatments. <i>Genes and Diseases</i> , 2022, 9, 12-27.	1.5	94
620	Deubiquitinases in hematological malignancies. <i>Biomarker Research</i> , 2021, 9, 66.	2.8	7
621	Exploiting epigenetic dependencies in ovarian cancer therapy. <i>International Journal of Cancer</i> , 2021, 149, 1732-1743.	2.3	22
622	Long Noncoding RNAs as Emerging Regulators of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 700184.	2.2	29
623	Polycomb Repressive Complex 2 Modulation through the Development of EZH2â€œEED Interaction Inhibitors and EED Binders. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11774-11797.	2.9	25
624	Going beyond Polycomb: EZH2 functions in prostate cancer. <i>Oncogene</i> , 2021, 40, 5788-5798.	2.6	40
625	PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis. <i>Clinical Epigenetics</i> , 2021, 13, 156.	1.8	10
626	Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and it is associated with immune infiltration. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	0.6	5
627	Maternal High-Fat Diet Promotes Abdominal Aortic Aneurysm Expansion in Adult Offspring by Epigenetic Regulation of IRF8-Mediated Osteoclast-like Macrophage Differentiation. <i>Cells</i> , 2021, 10, 2224.	1.8	2
628	Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1798-1809.	0.5	61
629	The progress of research on histone methylation in ischemic stroke pathogenesis. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 1-8.	1.3	7

#	ARTICLE	IF	CITATIONS
630	Single-Cell Analyses Reveal Mechanisms of Cancer Stem Cell Maintenance and Epithelialâ€“Mesenchymal Transition in Recurrent Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 27, 6265-6278.	3.2	43
631	EZH2 Inhibitor Enhances the STING Agonistâ€™Induced Antitumor Immunity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1158-1170.e8.	0.3	14
632	Pyroptosis in Steatohepatitis and Liver Diseases. <i>Journal of Molecular Biology</i> , 2022, 434, 167271.	2.0	17
633	Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis. <i>Leukemia</i> , 2021, , .	3.3	4
634	Differential requirement for the Polycomb repressor complex 2 in dendritic cell and tissue-resident myeloid cell homeostasis. <i>Science Immunology</i> , 2021, 6, eabf7268.	5.6	3
635	FusionAI: Predicting Fusion Breakpoint from DNA Sequence with Deep Learning. <i>IScience</i> , 2021, 24, 103164.	1.9	5
636	Recent Advances in Understanding the Mechanisms of Elemene in Reversing Drug Resistance in Tumor Cells: A Review. <i>Molecules</i> , 2021, 26, 5792.	1.7	14
637	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 1089-1101.	3.8	32
638	Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study. <i>Journal of Histotechnology</i> , 2021, , 1-8.	0.2	0
639	Aberrant activation of m6A demethylase FTO renders HIF2 ^{low} clear cell renal cell carcinoma sensitive to BRD9 inhibitors. <i>Science Translational Medicine</i> , 2021, 13, eabf6045.	5.8	28
640	Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 336-354.	2.0	14
641	Histone methylation in pancreatic cancer and its clinical implications. <i>World Journal of Gastroenterology</i> , 2021, 27, 6004-6024.	1.4	12
642	PBDEs affect inflammatory and oncosuppressive mechanisms via the EZH2 methyltransferase in airway epithelial cells. <i>Life Sciences</i> , 2021, 282, 119827.	2.0	10
643	An update on allosteric modulators as a promising strategy targeting histone methyltransferase. <i>Pharmacological Research</i> , 2021, 172, 105865.	3.1	5
644	Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113588.	2.6	20
645	Histone methylatic modification mediates the tumor-suppressive activity of curcumin in hepatocellular carcinoma via an H3ac/EZH2 regulatory axis. <i>Journal of Ethnopharmacology</i> , 2021, 280, 114413.	2.0	14
646	Developments of CRBN-based PROTACs as potential therapeutic agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113749.	2.6	64
647	PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. <i>Theranostics</i> , 2021, 11, 3742-3759.	4.6	30

#	ARTICLE	IF	CITATIONS
648	Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 2295-2316.	1.2	26
649	YY1 regulation of the cancer stem cell phenotype. , 2021, , 39-57.		0
650	Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity. <i>Journal of Biological Chemistry</i> , 2021, 296, 100349.	1.6	8
651	EZH2 Exacerbates Breast Cancer by Methylating and Activating STAT3 Directly. <i>Journal of Cancer</i> , 2021, 12, 5220-5230.	1.2	12
652	Epigenetic Control Using Small Molecules in Cancer. <i>Human Perspectives in Health Sciences and Technology</i> , 2020, , 111-148.	0.2	2
653	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3059-3082.	1.3	61
654	Clinical Implications of Primary Cilia in Skin Cancer. <i>Dermatology and Therapy</i> , 2020, 10, 233-248.	1.4	8
655	Epigenetic regulation of cancer stem cell and tumorigenesis. <i>Advances in Cancer Research</i> , 2020, 148, 1-26.	1.9	12
656	Functional Genomics for Cancer Drug Target Discovery. <i>Cancer Cell</i> , 2020, 38, 31-43.	7.7	46
657	Chromatin dependencies in cancer and inflammation. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 245-261.	16.1	64
658	Modeling medulloblastoma in vivo and with human cerebellar organoids. <i>Nature Communications</i> , 2020, 11, 583.	5.8	105
659	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	5.8	44
663	Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 37-46.	1.6	8
664	Relationship between EZH2 and VEGF expression and prognosis in colorectal cancer. <i>World Chinese Journal of Digestology</i> , 2020, 28, 155-166.	0.0	2
665	Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 759-773.	3.9	56
666	EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress. <i>Cancer Cell International</i> , 2020, 20, 175.	1.8	15
667	Symphony of epigenetic and metabolic regulationâ€™interaction between the histone methyltransferase EZH2 and metabolism of tumor. <i>Clinical Epigenetics</i> , 2020, 12, 72.	1.8	33
668	Epigenetic regulation of oligodendrocyte myelination in developmental disorders and neurodegenerative diseases. <i>F1000Research</i> , 2020, 9, 105.	0.8	28

#	ARTICLE	IF	CITATIONS
669	EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PLoS ONE, 2020, 15, e0242191.	1.1	20
670	Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1. Aging, 2019, 11, 3811-3823.	1.4	45
671	Ring finger protein 2 promotes colorectal cancer progression by suppressing early growth response 1. Aging, 2020, 12, 26199-26220.	1.4	11
672	GSK3 β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget, 2016, 7, 57131-57144.	0.8	35
673	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget, 2016, 7, 85624-85640.	0.8	44
674	Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing. Oncotarget, 2016, 7, 81715-81726.	0.8	7
675	Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget, 2017, 8, 3396-3411.	0.8	59
676	Opposing roles of <i>PIK3CA</i> gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget, 2017, 8, 10531-10542.	0.8	11
677	CBX7 is a glioma prognostic marker and induces G1/S arrest via the silencing of CCNE1. Oncotarget, 2017, 8, 26637-26647.	0.8	25
678	DNA methylation of METTL7A gene body regulates its transcriptional level in thyroid cancer. Oncotarget, 2017, 8, 34652-34660.	0.8	36
679	Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget, 2017, 8, 37974-37990.	0.8	61
680	miR-708-5p: a microRNA with emerging roles in cancer. Oncotarget, 2017, 8, 71292-71316.	0.8	49
681	The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget, 2017, 8, 68557-68570.	0.8	49
682	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	0.8	23
683	A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population. Oncotarget, 2017, 8, 94738-94742.	0.8	4
684	EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma. Oncotarget, 2017, 8, 96239-96248.	0.8	20
685	Targeting PRC2: RNA offers new opportunities. Oncotarget, 2017, 8, 107346-107347.	0.8	3
686	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. Oncotarget, 2017, 8, 115002-115017.	0.8	6

#	ARTICLE	IF	CITATIONS
687	EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. <i>Oncotarget</i> , 2018, 9, 21930-21942.	0.8	24
688	Limitations of current <i>in vitro</i> models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. <i>Oncotarget</i> , 2018, 9, 36530-36541.	0.8	7
689	Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression. <i>Oncotarget</i> , 2018, 9, 37054-37068.	0.8	14
690	Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme. <i>Oncotarget</i> , 2020, 11, 4754-4769.	0.8	7
691	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1712-1712.	0.7	36
692	Ezh2-dependent therapies in bladder cancer: synthetic lethality. <i>Annals of Translational Medicine</i> , 2017, 5, 494-494.	0.7	3
693	Next frontiers in systemic therapy for soft tissue sarcoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 43-43.	0.4	11
694	Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. <i>Current Medicinal Chemistry</i> , 2019, 26, 1328-1350.	1.2	13
695	Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2). <i>Current Cancer Drug Targets</i> , 2019, 19, 729-741.	0.8	11
696	Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2519-2526.	0.5	16
697	Polycomb and Trithorax Group Proteins: The Long Road from Mutations in <i>Drosophila</i> to Use in Medicine. <i>Acta Naturae</i> , 2020, 12, 66-85.	1.7	12
698	Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity. <i>Cancers</i> , 2020, 12, 2792.	1.7	26
699	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.	1.1	51
700	Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 1715-1728.	1.4	39
701	miR-144-3p inhibits tumor cell growth and invasion in oral squamous cell carcinoma through the downregulation of the oncogenic gene, EZH2. <i>International Journal of Molecular Medicine</i> , 2020, 46, 828-838.	1.8	16
702	Clinical significance of chromatin remodeling factor CHD5 expression in gastric cancer. <i>Oncology Letters</i> , 2020, 19, 1066-1073.	0.8	9
703	Influence of miR-101 on proliferation of liver cancer cells through the MAPK/ERK signaling pathway. <i>Oncology Letters</i> , 2020, 19, 1310-1316.	0.8	7
704	lncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines. <i>Oncology Letters</i> , 2020, 19, 1505-1515.	0.8	18

#	ARTICLE	IF	CITATIONS
705	Determination of long non-coding RNAs associated with EZH2 in neuroblastoma by RIP-seq, RNA-seq and ChIP-seq. <i>Oncology Letters</i> , 2020, 20, 1.	0.8	21
706	Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
707	Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. <i>Asian Journal of Andrology</i> , 2019, 21, 253.	0.8	17
708	Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. <i>World Journal of Stem Cells</i> , 2019, 11, 920-936.	1.3	17
709	LncRNA NRON promotes the proliferation, metastasis and EMT process in bladder cancer. <i>Journal of Cancer</i> , 2020, 11, 1751-1760.	1.2	19
710	Antagonistic interaction between Ezh2 and Arid1a coordinates root patterning and development via Cdkn2a in mouse molars. <i>ELife</i> , 2019, 8, .	2.8	16
711	The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. <i>ELife</i> , 2020, 9, .	2.8	168
712	<i>ARID1A</i> alterations and their clinical significance in cholangiocarcinoma. <i>PeerJ</i> , 2020, 8, e10464.	0.9	9
713	EZH2-mediated epigenetic suppression of lncRNA PCAT18 predicts a poor prognosis and regulates the expression of p16 by interacting with miR-570a-3p in gastric cancer. <i>Journal of Cancer</i> , 2021, 12, 7069-7078.	1.2	8
714	An overview of the development of EED inhibitors to disable the PRC2 function. <i>RSC Medicinal Chemistry</i> , 2022, 13, 39-53.	1.7	8
715	Polycomb group proteins in cancer: multifaceted functions and strategies for modulation. <i>NAR Cancer</i> , 2021, 3, zcab039.	1.6	10
716	Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. <i>Cancer Discovery</i> , 2021, 11, 2707-2725.	7.7	65
717	Tumor-suppressive function of EZH2 is through inhibiting glutaminase. <i>Cell Death and Disease</i> , 2021, 12, 975.	2.7	6
718	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. <i>Advanced Materials</i> , 2022, 34, e2100096.	11.1	24
719	Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14540-14556.	2.9	14
720	Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 755805.	1.5	17
721	BRD4 Regulates Transcription Factor <i>Notch1</i> to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas. <i>Cancer Research</i> , 2021, 81, 6246-6258.	0.4	9
722	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). <i>Cancers</i> , 2021, 13, 5014.	1.7	9

#	ARTICLE	IF	CITATIONS
723	The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. Life Sciences, 2021, 286, 120047.	2.0	15
730	Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. Current Cancer Research, 2018, , 327-352.	0.2	0
731	Renal Medullary Carcinoma. , 2019, , 65-75.		2
732	Therapeutic Modulators of Apoptosis and Epigenetics in Aggressive Lymphoma. Springer Reference Medizin, 2019, , 325-341.	0.0	0
733	Tissue and Circulating Biomarkers in Mesothelioma. , 2019, , 123-138.		0
739	ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. Molecular Medicine, 2021, 27, 138.	1.9	8
741	H3K36 trimethylation-mediated biological functions in cancer. Clinical Epigenetics, 2021, 13, 199.	1.8	25
742	Primary Epithelioid Sarcoma of the Oral Cavity: Review of Literature and Presentation of a Rare Entity. Oral Surgery, 0, , .	0.1	0
743	LncRNAs in the Development, Progression, and Therapy Resistance of Hormone-Dependent Cancer. RNA Technologies, 2020, , 255-276.	0.2	0
744	Chromatin Immunoprecipitation Followed by Next-Generation Sequencing (ChIP-Seq) Analysis in Ewing Sarcoma. Methods in Molecular Biology, 2021, 2226, 265-284.	0.4	2
745	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. , 2020, , 231-255.		1
746	Chromatin plasticity in pluripotent and cancer stem cells. , 2020, , 207-230.		0
747	Cancer Stem Cells and the Development of Cancer. Learning Materials in Biosciences, 2020, , 151-192.	0.2	0
748	Novel Natural Inhibitors Targeting Enhancer of Zeste Homolog 2: A Comprehensive Structural Biology Research. Frontiers in Oncology, 2021, 11, 741403.	1.3	4
749	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications, 2021, 12, 6276.	5.8	89
750	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	5.8	35
753	Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review). International Journal of Oncology, 2020, 57, 631-664.	1.4	28
756	Targeted detection and quantitation of histone modifications from 1,000 cells. PLoS ONE, 2020, 15, e0240829.	1.1	3

#	ARTICLE	IF	CITATIONS
759	lncRNA H19 promotes tongue squamous cell carcinoma progression through β -catenin/GSK3 β /EMT signaling via association with EZH2. American Journal of Translational Research (discontinued), 2017, 9, 3474-3486.	0.0	30
760	The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer. American Journal of Translational Research (discontinued), 2017, 9, 5496-5506.	0.0	36
761	EZH2 Expression in Naturally Occurring Canine Tumors. Comparative Medicine, 2018, 68, 148-155.	0.4	3
762	USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization. Molecules and Cells, 2019, 42, 17-27.	1.0	22
763	Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. American Journal of Clinical and Experimental Urology, 2019, 7, 85-91.	0.4	14
764	Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination. American Journal of Cancer Research, 2019, 9, 1695-1707.	1.4	36
765	Indirect Tumor Inhibitory Effects of MicroRNA-124 through Targeting EZH2 in The Multiple Myeloma Cell Line. Cell Journal, 2020, 22, 23-29.	0.2	3
766	Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER α expression in high-grade serous ovarian carcinoma. American Journal of Cancer Research, 2020, 10, 1194-1206.	1.4	4
768	Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. American Journal of Cancer Research, 2020, 10, 3267-3284.	1.4	4
769	Epigenetically silenced linc00261 contributes to the metastasis of hepatocellular carcinoma via inducing the deficiency of FOXA2 transcription. American Journal of Cancer Research, 2021, 11, 277-296.	1.4	4
770	Development of a UPLC-MS/MS method for determination of a dual EZH1/2 inhibitor UNC1999 in rat plasma. Bioanalysis, 2022, 14, 67-74.	0.6	1
771	Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+/tamoxifen treated breast cancer patients. Journal of Genetics, 2021, 100, 1.	0.4	3
772	PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death and Disease, 2021, 12, 1080.	2.7	31
773	CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	6
774	Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment. Xenobiotica, 2022, 52, 65-78.	0.5	6
775	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. Therapie, 2021, , .	0.6	1
776	Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Laboratory Investigation, 2022, 102, 185-193.	1.7	8
777	EZH2 Inhibition Compromises β 4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells. Frontiers in Immunology, 2021, 12, 770080.	2.2	0

#	ARTICLE	IF	CITATIONS
778	Role of Rho guanine nucleotide exchange factors in non-small cell lung cancer. <i>Bioengineered</i> , 2021, 12, 11169-11187.	1.4	7
780	Pathogen-Induced Epigenetic Modifications in Cancers: Implications for Prevention, Detection and Treatment of Cancers in Africa. <i>Cancers</i> , 2021, 13, 6051.	1.7	8
782	EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. <i>Nature Communications</i> , 2022, 13, 12.	5.8	64
783	EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112532.	2.5	24
784	Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112123.	2.5	6
785	Anticancer chiral and racemic ternary copper(II) complexes: Multiple mechanisms and epigenetic histone methyltransferase enzymes as novel targets. <i>Polyhedron</i> , 2022, 213, 115617.	1.0	3
786	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	2.0	7
787	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	22
788	Mechanisms of Polycomb group protein function in cancer. <i>Cell Research</i> , 2022, 32, 231-253.	5.7	52
789	Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1662-1684.	2.9	11
790	The transcriptional elongation factor CTR9 demarcates PRC2-mediated H3K27me3 domains by altering PRC2 subtype equilibrium. <i>Nucleic Acids Research</i> , 2022, 50, 1969-1992.	6.5	6
791	Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. <i>Nature Reviews Cancer</i> , 2022, 22, 157-173.	12.8	125
792	Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. <i>Leukemia</i> , 2022, 36, 1048-1057.	3.3	5
793	Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds. <i>Cancers</i> , 2022, 14, 563.	1.7	7
794	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. <i>Cancers</i> , 2022, 14, 679.	1.7	4
795	Tick tock, tick tock: Mouse culture and tissue aging captured by an epigenetic clock. <i>Aging Cell</i> , 2022, 21, e13553.	3.0	19
796	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. <i>European Journal of Cancer</i> , 2022, 163, 44-54.	1.3	14
797	A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 377-387.	1.3	10

#	ARTICLE	IF	CITATIONS
798	Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis. <i>Cancer Research</i> , 2022, 82, 1208-1221.	0.4	8
799	Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor. <i>EBioMedicine</i> , 2022, 77, 103872.	2.7	16
800	Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma. <i>JID Innovations</i> , 2022, 2, 100090.	1.2	4
801	MicroRNA-217: a therapeutic and diagnostic tumor marker. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 61-76.	1.5	11
803	The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100541.	0.7	0
804	An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac018.	0.4	2
805	Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. <i>Cancer Management and Research</i> , 2022, Volume 14, 479-498.	0.9	11
806	EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. <i>Nature Cell Biology</i> , 2022, 24, 384-399.	4.6	88
807	A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
808	Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer. <i>Nutrients</i> , 2022, 14, 851.	1.7	17
809	Epigenetic Regulation: A Link between Inflammation and Carcinogenesis. <i>Cancers</i> , 2022, 14, 1221.	1.7	15
810	Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. <i>Bladder Cancer</i> , 2022, 8, 101-112.	0.2	4
811	Scutellarin suppresses triple-negative breast cancer metastasis by inhibiting TNF α -induced vascular endothelial barrier breakdown. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2666-2677.	2.8	7
812	MYPT1/PP1 α -Mediated EZH2 Dephosphorylation at S21 Promotes Epithelial \rightarrow Mesenchymal Transition in Fibrosis through Control of Multiple Families of Genes. <i>Advanced Science</i> , 2022, 9, e2105539.	5.6	10
813	EZH2 and Endometrial Cancer Development: Insights from a Mouse Model. <i>Cells</i> , 2022, 11, 909.	1.8	5
815	Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition. <i>Cancer Research</i> , 2022, 82, 2019-2030.	0.4	9
816	H3K27me3 Demethylase UTX Restrains Plasma Cell Formation. <i>Journal of Immunology</i> , 2022, 208, 1873-1885.	0.4	3
817	Ketogenic Diet as Adjunctive Therapy for Malignant Brain Cancer. , 2022, , 125-153.		0

#	ARTICLE	IF	CITATIONS
818	The histidine phosphatase LHPP: an emerging player in cancer. <i>Cell Cycle</i> , 2022, 21, 1140-1152.	1.3	6
819	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 47.	2.4	11
820	Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 63, 128653.	1.0	18
821	A novel navigated doxorubicin delivery formulation to breast cancer therapy. <i>Materials Today Advances</i> , 2022, 14, 100235.	2.5	3
822	microRNA-150 targets major epigenetic repressors and inhibits cell proliferation. <i>Experimental Cell Research</i> , 2022, 415, 113110.	1.2	1
823	Repurposing Market Drugs to Target Epigenetic Enzymes in Human Diseases. , 0, , .		0
824	Dual targeting, a new strategy for novel PARP inhibitor discovery. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 300-309.	0.6	7
825	Small molecule targeting of chromatin writers in cancer. <i>Nature Chemical Biology</i> , 2022, 18, 124-133.	3.9	19
826	Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. <i>Diagnostics</i> , 2022, 12, 61.	1.3	10
827	Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF- κ B p65 pathway. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2067-2080.	2.8	13
828	HAUSP Is a Key Epigenetic Regulator of the Chromatin Effector Proteins. <i>Genes</i> , 2022, 13, 42.	1.0	2
829	Tracking the Dynamic Histone Methylation of H3K27 in Live Cancer Cells. <i>ACS Sensors</i> , 2021, 6, 4369-4378.	4.0	5
830	The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines. <i>Cancers</i> , 2022, 14, 41.	1.7	5
831	Sex disparities in thyroid cancer: a SEER population study. <i>Gland Surgery</i> , 2021, 10, 3200-3210.	0.5	13
832	Insights of RKIP-Derived Suppression of Prostate Cancer. <i>Cancers</i> , 2021, 13, 6388.	1.7	6
833	Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer. <i>Frontiers in Chemistry</i> , 2022, 10, 837987.	1.8	8
834	Epigenetic Regulation of Chondrocytes and Subchondral Bone in Osteoarthritis. <i>Life</i> , 2022, 12, 582.	1.1	8
835	Nuclear translocation of p85 ¹² promotes tumorigenesis of PIK3CA helical domain mutant cancer. <i>Nature Communications</i> , 2022, 13, 1974.	5.8	13

#	ARTICLE	IF	CITATIONS
879	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 715-726.	1.9	11
882	DNA binding by polycomb-group proteins: searching for the link to CpG islands. <i>Nucleic Acids Research</i> , 2022, 50, 4813-4839.	6.5	15
883	USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF- κ B/PD-L1 axis to promote the development of cervical cancer. <i>Cellular Signalling</i> , 2022, 96, 110351.	1.7	4
884	EZH2 engages TGF β 2 signaling to promote breast cancer bone metastasis via integrin β 1-FAK activation. <i>Nature Communications</i> , 2022, 13, 2543.	5.8	50
885	Regulation of developmental hierarchy in <i>Drosophila</i> neural stem cell tumors by COMPASS and Polycomb complexes. <i>Science Advances</i> , 2022, 8, eabi4529.	4.7	2
886	Long-Distance Repression by Human Silencers: Chromatin Interactions and Phase Separation in Silencers. <i>Cells</i> , 2022, 11, 1560.	1.8	8
887	NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. <i>Molecular Cell</i> , 2022, 82, 2472-2489.e8.	4.5	18
888	Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7016-7043.	2.9	10
889	3D chromatin architecture and transcription regulation in cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, 49.	6.9	22
890	Identification of a cytosine-based EED-EZH2 protein-protein interaction inhibitor preventing metastasis in triple-negative breast cancer cells. , 2022, 1, .		10
891	High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. <i>Genes</i> , 2022, 13, 876.	1.0	5
892	EpimRNAs: Modern mediators of methylation status in human cancers. <i>Wiley Interdisciplinary Reviews RNA</i> , 2023, 14, e1735.	3.2	5
893	Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3K inhibitors in oesophageal squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	8
894	Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus. <i>EBioMedicine</i> , 2022, 80, 104056.	2.7	19
895	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114462.	2.6	20
896	PHF13 epigenetically activates TGF β 2 driven epithelial to mesenchymal transition. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
897	Rutin induces endoplasmic reticulum stress-associated apoptosis in human triple-negative breast carcinoma MDA-MB-231 cells – In vitro and in silico docking studies. <i>Arabian Journal of Chemistry</i> , 2022, 15, 104021.	2.3	3
898	Super-Enhancers, Phase-Separated Condensates, and 3D Genome Organization in Cancer. <i>Cancers</i> , 2022, 14, 2866.	1.7	16

#	ARTICLE	IF	CITATIONS
899	EZH2 Promotes T Follicular Helper Cell Differentiation Through Enhancing STAT3 Phosphorylation in Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
900	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	77
901	Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. <i>Cancers</i> , 2022, 14, 2828.	1.7	2
902	A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121894.	2.6	5
903	Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. , 0, , 45-60.		1
904	Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degradator of Enhancer of Zeste Homolog 2. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 491-507.	2.5	21
905	Machine-learning-optimized Cas12a barcoding enables the recovery of single-cell lineages and transcriptional profiles. <i>Molecular Cell</i> , 2022, 82, 3103-3118.e8.	4.5	14
906	Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
907	EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization. <i>Oncogene</i> , 2022, 41, 3611-3624.	2.6	6
908	Chemical biology and pharmacology of histone lysine methylation inhibitors. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2022, 1865, 194840.	0.9	12
909	Systems Drug Discovery for Diffuse Large B Cell Lymphoma Based on Pathogenic Molecular Mechanism via Big Data Mining and Deep Learning Method. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6732.	1.8	2
910	Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders. <i>Cancer Cell International</i> , 2022, 22, .	1.8	11
911	PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
912	SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	4
913	LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	16
914	Insights Into the Properties, Biological Functions, and Regulation of USP21. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
915	Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical <i>In Vivo</i> Models of Esophageal Squamous Cell Cancer. <i>Anticancer Research</i> , 2022, 42, 3233-3249.	0.5	1
916	Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth. <i>IScience</i> , 2022, 25, 104752.	1.9	2

#	ARTICLE	IF	CITATIONS
917	Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating EZH2-mediated methylation of CHST7. <i>Aging</i> , 2022, 14, 5523-5536.	1.4	5
918	DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability. <i>Oncogene</i> , 2022, 41, 3991-4002.	2.6	17
919	Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. <i>Metabolites</i> , 2022, 12, 652.	1.3	4
920	Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 306-318.	0.8	8
921	Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy. <i>Pharmacological Research</i> , 2022, 182, 106333.	3.1	26
922	SASH1 knockdown suppresses TRAF6 ubiquitination to regulate hemangioma progression by mediating EZH2 degradation. <i>Experimental Cell Research</i> , 2022, 418, 113270.	1.2	5
923	The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications. <i>Protein and Cell</i> , 0, , .	4.8	1
924	EZH2 regulates a SETDB1/HP1 axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma. <i>Oncogene</i> , 2022, 41, 4130-4144.	2.6	9
925	LncRNA JPX Targets SERCA2a to Mitigate Myocardial Ischemia/Reperfusion Injury by Binding to EZH2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
927	The crucial roles of long noncoding RNA SNHG3 in lung cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 2272-2284.	1.2	2
928	Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. <i>Nature Communications</i> , 2022, 13, .	5.8	22
930	FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3. <i>Bioscience Reports</i> , 2022, 42, .	1.1	3
931	Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. <i>Science Immunology</i> , 2022, 7, .	5.6	35
932	Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. <i>Nature Communications</i> , 2022, 13, .	5.8	18
933	Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells. <i>Molecules and Cells</i> , 2022, 45, 550-563.	1.0	4
934	Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias. <i>Blood</i> , 2022, 140, 2358-2370.	0.6	9
935	EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression. <i>IScience</i> , 2022, 25, 104827.	1.9	4
936	Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9574.	1.8	6

#	ARTICLE	IF	CITATIONS
937	Mechanical stretch aggravates vascular smooth muscle cell apoptosis and vascular remodeling by downregulating EZH2. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 151, 106278.	1.2	3
938	Chemistries of bifunctional PROTAC degraders. <i>Chemical Society Reviews</i> , 2022, 51, 7066-7114.	18.7	73
939	<scp>miRNAs</scp> in prostate cancer: Intercellular and extracellular communications. <i>International Journal of Urology</i> , 2022, 29, 1429-1438.	0.5	6
940	Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma. <i>Pathology Research and Practice</i> , 2022, 238, 154071.	1.0	2
941	USP21 accelerates the proliferation and glycolysis of esophageal cancer cells by regulating the STAT3/FOXO1 pathway. <i>Tissue and Cell</i> , 2022, 79, 101916.	1.0	5
942	Epigenetic therapy and DNA damage response. , 2022, , 227-252.		0
943	Epigenetic Events in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
944	Polycomb-group proteins and epigenetic control of gene activity. , 2023, , 111-120.		0
945	ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. <i>JCI Insight</i> , 2022, 7, .	2.3	18
946	Epigenetic modifications: Critical participants of the PD&L1 regulatory mechanism in solid tumors (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
947	Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11393.	1.8	1
948	lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia. <i>Stem Cells International</i> , 2022, 2022, 1-20.	1.2	4
949	Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. <i>Vaccines</i> , 2022, 10, 1448.	2.1	3
950	Polycomb Directed Cell Fate Decisions in Development and Cancer. <i>Epigenomes</i> , 2022, 6, 28.	0.8	8
951	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 1419-1428.	0.5	4
952	Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. <i>Journal of Gastroenterology</i> , 2022, 57, 819-826.	2.3	3
953	EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. <i>BMC Cancer</i> , 2022, 22, .	1.1	8
954	EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies. <i>Cancers</i> , 2022, 14, 4761.	1.7	9

#	ARTICLE	IF	CITATIONS
955	Hydrophobic Tag Tethering Degradation, The Emerging Targeted Protein Degradation Strategy. <i>Current Medicinal Chemistry</i> , 2023, 30, 3137-3155.	1.2	2
956	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
957	Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. <i>Science Advances</i> , 2022, 8, .	4.7	13
958	Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
959	Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 14-25.	2.0	10
960	Current understanding of epigenetics role in melanoma treatment and resistance. <i>Cancer Cell International</i> , 2022, 22, .	1.8	15
961	EZH2: Its regulation and roles in immune disturbance of SLE. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
962	EZH2 regulates oncomiR-200c and EMT markers in esophageal squamous cell carcinomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
963	A GRIP-1â€EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a. <i>Oncogene</i> , 2022, 41, 5223-5237.	2.6	3
964	Epigenetic factor competition reshapes the EMT landscape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	5
965	The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy. <i>International Journal of Hematology</i> , 0, , .	0.7	2
966	Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14276-14288.	2.9	17
967	A cryptic transactivation domain of EZH2 binds AR and ARâ€™s splice variant, promoting oncogene activation and tumorous transformation. <i>Nucleic Acids Research</i> , 2022, 50, 10929-10946.	6.5	12
968	HUSH-mediated HIV silencing is independent of TASOR phosphorylation on threonine 819. <i>Retrovirology</i> , 2022, 19, .	0.9	2
969	GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-ÎB/IL1 Pathways. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13915.	1.8	5
970	Machine learning algorithm and deep neural networks identified a novel subtype in hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2022, 35, 305-320.	0.8	2
971	New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	11
972	Improving Treatment Strategies for Patients with Follicular Lymphoma: How to Translate Novel Study Data into Clinical Practice. <i>European Medical Journal Hematology</i> , 0, , 2-10.	0.0	0

#	ARTICLE	IF	CITATIONS
973	Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	14
974	Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. <i>Leukemia Research</i> , 2023, 124, 106999.	0.4	3
975	Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition. <i>Biomaterials</i> , 2023, 293, 121952.	5.7	8
976	Effective role of Curcumin on expression regulation of EZH2 histone methyltransferase as a dynamic epigenetic factor in osteogenic differentiation of human mesenchymal stem cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2023, 1866, 194903.	0.9	2
977	Association of EZH2 Genotypes With Oral Cancer Risk. <i>In Vivo</i> , 2022, 36, 2669-2677.	0.6	1
978	Primary extranodal diffuse large B-cell lymphoma: Molecular features, treatment, and prognosis. <i>Aging and Cancer</i> , 2022, 3, 133-146.	0.5	0
979	EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. <i>Nature Communications</i> , 2022, 13, .	5.8	24
980	Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	1
981	The clinical relationship between histamine-1 receptor antagonists and risk of cancer: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	2
982	Zinc finger myeloid Nery DEAF-1 type (ZMYND) domain containing proteins exert molecular interactions to implicate in carcinogenesis. <i>Discover Oncology</i> , 2022, 13, .	0.8	3
983	Cancer epigenetics in clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 376-424.	157.7	43
984	Importance of pharmacologic considerations in the development of targeted anticancer agents for children. <i>Current Opinion in Pediatrics</i> , 0, Publish Ahead of Print, .	1.0	0
985	EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes. <i>American Journal of Pathology</i> , 2022, 192, 1712-1724.	1.9	3
986	Epigenetic Regulation in Urothelial Carcinoma. <i>Current Molecular Medicine</i> , 2022, 23, .	0.6	0
987	EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. <i>Oncogene</i> , 2023, 42, 461-470.	2.6	2
988	Role of EZH2 in Uterine Gland Development. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15665.	1.8	4
989	The cancer epigenome: Non-cell autonomous player in tumor immunity. <i>Cancer Science</i> , 2023, 114, 730-740.	1.7	2
990	Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
991	Impact of epigenetic reprogramming on antitumor immune responses in glioma. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	15
992	Human ERG oncoprotein represses <i>Drosophila</i> LIM domain binding proteinâ€‘coding gene <i>Chip</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	0
993	EZH2: An Accomplice of Gastric Cancer. <i>Cancers</i> , 2023, 15, 425.	1.7	10
994	Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. <i>Epigenomics</i> , 2022, 14, 1449-1464.	1.0	2
995	Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. <i>Biomedicines</i> , 2023, 11, 169.	1.4	0
996	SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression. <i>American Journal of Pathology</i> , 2023, 193, 456-473.	1.9	3
997	Editorial: Epigenetic regulation and therapy resistance in cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
998	Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
999	Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	3
1000	Changes in PRC1 activity during interphase modulate lineage transition in pluripotent cells. <i>Nature Communications</i> , 2023, 14, .	5.8	1
1001	First Korean Case of Weaver Syndrome Along with Neuroblastoma and Genetic Confirmation of <i>EZH2</i> Variant. <i>Laboratory Medicine Online</i> , 2023, 13, 48-52.	0.0	2
1002	The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1003	MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas. <i>Cancers</i> , 2023, 15, 577.	1.7	0
1004	Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent. <i>Cancers</i> , 2023, 15, 208.	1.7	1
1005	Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer. <i>Endocrinology</i> , 0, , .	1.4	0
1006	Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. , 2023, , 201-235.		1
1008	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	7
1009	Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors. <i>Nature Communications</i> , 2023, 14, .	5.8	4

#	ARTICLE	IF	CITATIONS
1010	Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 1725-1741.	2.9	12
1012	Chromobox proteins in cancer: Multifaceted functions and strategies for modulation (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	4
1013	Modulation of epigenetic methylation enzymes by synthetic and natural agents. , 2023, , 325-357.		0
1015	Exosomes from LSD1 knockdown breast cancer cells activate osteoclastogenesis and inhibit osteoblastogenesis. <i>International Journal of Biological Macromolecules</i> , 2023, 235, 123792.	3.6	4
1016	The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy. <i>Pathology Research and Practice</i> , 2023, 245, 154437.	1.0	40
1017	LncRNA JPX targets SERCA2a to mitigate myocardial ischemia/reperfusion injury by binding to EZH2. <i>Experimental Cell Research</i> , 2023, 427, 113572.	1.2	5
1018	miRNA let-7a inhibits invasion, migration, anchorage-independent growth by suppressing EZH2 and promotes mesenchymal to epithelial transition in MDAMB-231. <i>Gene Reports</i> , 2023, 31, 101752.	0.4	1
1019	EZH2 inhibition dampens autoantibody production in lupus by restoring B cell immune tolerance. <i>International Immunopharmacology</i> , 2023, 119, 110155.	1.7	1
1020	EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	2
1021	Epigenetic reactivation of PEG3 by EZH2 inhibitors suppresses renal clear cell carcinoma progress. <i>Cellular Signalling</i> , 2023, 107, 110662.	1.7	3
1022	The role of EZH2 as a potential therapeutic target in retinoblastoma. <i>Experimental Eye Research</i> , 2023, 227, 109389.	1.2	2
1023	PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. <i>Molecules</i> , 2023, 28, 1217.	1.7	5
1024	G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 0, , .	1.4	2
1025	Dose-dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine. <i>Current Drug Targets</i> , 2023, 24, 371-378.	1.0	0
1027	YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
1028	Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2&BRD4 Inhibitor for the Treatment of Some Solid Tumors. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2646-2662.	2.9	10
1029	Overexpression of KMT9± Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer. <i>Cells</i> , 2023, 12, 589.	1.8	3
1030	Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4126.	1.8	3

#	ARTICLE	IF	CITATIONS
1031	SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. <i>Molecular Cancer</i> , 2023, 22, .	7.9	12
1032	Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1. <i>FEBS Open Bio</i> , 2023, 13, 724-735.	1.0	3
1033	Multifaceted Transcriptional Network of Estrogen-Related Receptor Alpha in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4265.	1.8	2
1034	Inhibitors targeting epigenetic modifications in cancer. , 2023, , 287-324.		0
1035	Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2023, 210, 115493.	2.0	0
1036	<i>Ezh2</i> Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in <i>MRL</i> Mice. <i>Arthritis and Rheumatology</i> , 2023, 75, 1395-1406.	2.9	1
1037	Two Onnamide Analogs from the Marine Sponge <i>Theonella conica</i> : Evaluation of Geometric Effects in the Polyene Systems on Biological Activity. <i>Molecules</i> , 2023, 28, 2524.	1.7	1
1038	UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. <i>Oncogene</i> , 2023, 42, 1360-1373.	2.6	2
1040	Role of Histone Modifications in the Progression of Cancer. , 2023, , 1-17.		0
1041	Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma. <i>Nature Chemical Biology</i> , 2023, 19, 1105-1115.	3.9	6
1042	LncRNA SLC25A21-AS1 increases the chemosensitivity and inhibits the progression of ovarian cancer by upregulating the expression of KCNK4. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	1
1043	EZH2 Methyltransferase Regulates Neuroinflammation and Neuropathic Pain. <i>Cells</i> , 2023, 12, 1058.	1.8	1
1044	UXT at the crossroads of cell death, immunity and neurodegenerative diseases. <i>Frontiers in Oncology</i> , 2023, 13, .	1.3	2
1046	Gain-of-Function Variomics and Multi-omics Network Biology for Precision Medicine. <i>Methods in Molecular Biology</i> , 2023, , 357-372.	0.4	0
1054	Writers, erasers, and readers of DNA and histone methylation marks. , 2023, , 39-63.		1
1055	Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors. , 2023, , 373-405.		0
1061	Chemically induced degradation of epigenetic targets. <i>Chemical Society Reviews</i> , 2023, 52, 4313-4342.	18.7	2
1064	Structural classification of EZH2 inhibitors and prospects for the treatment of tumor: a review. <i>Medicinal Chemistry Research</i> , 2023, 32, 1589-1604.	1.1	2

#	ARTICLE	IF	CITATIONS
1076	O-GlcNAcylation: A Crucial Regulator in Cancer-Associated Biological Events. <i>Cell Biochemistry and Biophysics</i> , 2023, 81, 383-394.	0.9	2
1083	Epigenetic inhibitors for cancer treatment. <i>International Review of Cell and Molecular Biology</i> , 2024, , 89-144.	1.6	0
1098	Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine. <i>Chemical Society Reviews</i> , 2023, 52, 5706-5743.	18.7	7
1100	Epigenetics behind tumor immunology: a mini review. <i>Oncogene</i> , 2023, 42, 2932-2938.	2.6	1
1104	Alterations of histone modifications in cancer. , 2024, , 85-172.		0
1121	miRNAs as biomarkers breast cancer and their influence on tumor epigenetics. , 2024, , 173-205.		0
1132	Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents. <i>Cancer Treatment and Research</i> , 2023, , 171-188.	0.2	0
1146	Polycomb Repressive Complex 2 in Oncology. <i>Cancer Treatment and Research</i> , 2023, , 273-320.	0.2	1